SINGAPORE, Nov. 03, 2026 (GLOBE NEWSWIRE) — Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading provider of customer engagement and marketing technology services, today announced that its AI-first customer engagement platform, EngageLab, has partnered with SKYWORTH Solar Co., Ltd. SKYWORTH Solar has deployed EngageLab AppPush within its international business operations to streamline communications for global channel distributors, project engineering teams and end users, reinforcing its ongoing global expansion.

Founded in 2020 as a subsidiary of Skyworth Group, SKYWORTH Solar specializes in residential and commercial photovoltaics, energy storage, charging, and smart energy operations. As the company accelerates its international footprint—operating via localized teams and an extensive distributor network across more than 40 countries—the need for a robust, global messaging infrastructure has become critical.

Overcoming Communication Fragmentation in Global Markets
For a company transitioning from hardware export to delivering comprehensive, end-to-end energy solutions, reliable communication is the backbone of operational efficiency. As SKYWORTH Solar entered diverse markets across Europe, Southeast Asia, the Middle East, and Africa, it faced a highly fragmented Android ecosystem.

By integrating the EngageLab AppPush solution, SKYWORTH Solar has unified its notification routing capabilities, overcoming the limitations of disparate device manufacturer channels. This integration ensures consistent, localized, and compliant data transmission during peak operational periods or critical policy rollouts.

Driving Efficiency Across Three Core Scenarios
With EngageLab AppPush, SKYWORTH Solar has successfully tailored its messaging strategies to meet the distinct needs of its diverse user base:

  • Streamlining Distributor Operations: The platform enables SKYWORTH Solar to distribute targeted updates regarding new product launches, pricing policies, inventory, and order statuses. Messages are intelligently scheduled and adapted to each distributor’s local time zone and device language, ensuring seamless operational alignment.
  • Empowering On-Site Engineering Teams: For field personnel, the app reliably delivers construction milestones, inspection tasks, and critical equipment alerts (such as inverter or battery anomalies). By integrating with major device manufacturer channels alongside standard routing options, EngageLab ensures these time-sensitive notifications reach teams even in challenging outdoor connectivity environments.
  • Enhancing the End-User Experience: Property owners receive prompt, periodic updates on energy generation and grid yields, as well as immediate alerts for any equipment anomalies, ensuring transparency and trust.

“As we expand our renewable energy solutions globally, staying connected with our distributors and field engineers in real time is paramount,” said the Head of Global Operations at SKYWORTH Solar. “EngageLab’s AppPush provides the reliability and intelligent routing we need to keep our international operations running smoothly.”

As SKYWORTH Solar continues to scale its channel network, this advanced communication infrastructure will grow in tandem. EngageLab remains committed to leveraging its AI-first engagement capabilities to help SKYWORTH Solar maintain synchronized, reliable, and context-aware communications with its global stakeholders.

About EngageLab
EngageLab is an AI-first customer engagement platform that helps you build stronger customer relationships with AI agents, unified customer data, and reliable delivery across channels. EngageLab’s global customers include Dhgate, HelloRide, The Consejo Nacional Electoral (CNE) of Ecuador, J&T Cargo, Blurams and many more.
For more information, please contact: marketing@engagelab.com

About Aurora Mobile Limited
Founded in 2011, Aurora Mobile (NASDAQ: JG) is a leading provider of customer engagement and marketing technology services. The Company is dedicated to empowering global enterprises with stable, efficient, and intelligent customer interaction solutions. Leveraging its first-mover advantage in mobile messaging, Aurora Mobile has evolved into a comprehensive platform that integrates Omnichannel Engagement, AI-Driven Marketing, Advanced AI Customer Support, and Frictionless Identity Security. Through its flagship brand EngageLab and its robust AI infrastructure GPTBots.ai, the Company helps businesses achieve seamless customer reach, automate complex marketing journeys, and optimize service efficiency with AI agents, accelerating digital transformation for clients worldwide.

For more information, please visit: https://ir.aurora-mobile.com/
Media contact: marketing@aurora-mobile.com

Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Among other things, the Business Outlook and quotations from management in this announcement, as well as Aurora Mobile’s strategic and operational plans, contain forward-looking statements. Aurora Mobile may also make written or oral forward-looking statements in its reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about Aurora Mobile’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Aurora Mobile’s strategies; Aurora Mobile’s future business development, financial condition and results of operations; Aurora Mobile’s ability to attract and retain customers; its ability to develop and effectively market data solutions, and penetrate the existing market for developer services; its ability to transition to the new advertising-driven SAAS business model; its ability to maintain or enhance its brand; the competition with current or future competitors; its ability to continue to gain access to mobile data in the future; the laws and regulations relating to data privacy and protection; general economic and business conditions globally and in China and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company’s filings with the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release, and Aurora Mobile undertakes no duty to update such information, except as required under applicable law.

For more information, please contact:
Aurora Mobile Limited
E-mail: ir@aurora-mobile.com

Christensen Advisory
Ms. Xiaoyan Su
E-mail: Xiaoyan.Su@christensencomms.com

Net Revenues Increased by 17.0% Year-over-Year to RMB17.9 Billion

GAAP Operating Income Increased by 55.1% Year-over-Year to RMB2.8 Billion, with Operating Margin Expanding to 15.4%

Average Monthly Transacting Customers Reached Another Record High of 123.0 Million

BEIJING, Nov. 03, 2026 (GLOBE NEWSWIRE) — Luckin Coffee Inc. (“Luckin Coffee” or the “Company”) (OTC: LKNCY) today announced its unaudited financial results for the three months ended September 30, 2026.

THIRD QUARTER 2026 HIGHLIGHTS1

  • Total net revenues were RMB17,891.5 million (US$2,666.0 million), representing a 17.0% year-over-year increase.
  • Net new store openings were 2,599, comprising 2,543 stores in China (including Hong Kong), 14 stores in Singapore, 40 stores in Malaysia and 2 stores in the U.S. Total number of stores increased to 38,909 at the third quarter end, comprising 25,402 self-operated stores and 13,507 partnership stores, which represented a store unit growth of 7.2% from the total store count as of the end of the second quarter of 2026.
  • Average monthly transacting customers reached another record high of 123.0 million, representing a 9.6% year-over-year increase.
  • Revenues from self-operated stores were RMB12,939.8 million (US$1,928.2 million), representing a 16.8% year-over-year increase.
  • Same-store sales growth for self-operated stores was negative 11.1%, compared to 14.3% in the same quarter of 2025, primarily reflecting a high prior-year comparison base due to elevated subsidies offered by food delivery platforms during the comparable period.
  • Store-level operating profit – self-operated stores was RMB3,019.3 million (US$449.9 million), representing a 55.5% year-over-year increase. Store-level operating margin improved by 5.8 percentage points year-over-year to 23.3%.
  • Revenues from partnership stores were RMB4,242.7 million (US$632.2 million), representing an 11.7% year-over-year increase.
  • GAAP operating income was RMB2,755.9 million (US$410.7 million), representing a 55.1% year-over-year increase. GAAP operating margin improved by 3.8 percentage points year-over-year to 15.4%. Non-GAAP operating income, which adjusts for share-based compensation expenses and deal-related expenses for long-term equity investment, was RMB3,047.0 million (US$454.0 million), representing a 58.2% year-over-year increase. Non-GAAP operating margin improved by 4.4 percentage points year-over-year to 17.0%.

Dr. Jinyi Guo, Co-founder and CEO of Luckin Coffee, said, “Our execution of the high-quality, scaled growth strategy continued to yield positive results. Amid growing coffee demand in China, our average monthly transacting customers reached another record high, while we maintained an industry-leading pace of store expansion. We also continued to improve profitability, with quarterly non-GAAP net income reaching a record RMB2.1 billion. These results further validate our digitally driven end-to-end business model and reinforce our confidence in capturing the secular growth opportunities in China’s coffee market. With this in mind, we are pleased to announce that our board has approved a new share repurchase program of up to US$500 million. Looking ahead, we remain focused on market share gains and long-term value creation for shareholders.”

__________________
1 Please refer to the section “KEY DEFINITIONS” for detailed definitions on certain terms used.

THIRD QUARTER 2026 FINANCIAL RESULTS

Total net revenues were RMB17,891.5 million (US$2,666.0 million), representing an increase of 17.0% from RMB15,287.1 million in the same quarter of 2025. Net revenues growth was primarily driven by a 19.7% year-over-year increase in GMV, which reached RMB20.7 billion, as a result of an increase in the number of products sold resulting from growth in (i) the number of stores in operation as well as (ii) monthly transacting customers.

  • Revenues from product sales were RMB13,648.7 million (US$2,033.8 million), representing an increase of 18.8% from RMB11,488.3 million in the same quarter of 2025.
    • Net revenues from freshly brewed drinks increased to RMB12,438.4 million (US$1,853.4 million) from RMB10,632.9 million in the same quarter of 2025. This revenue stream accounted for 69.5% of total net revenues, largely consistent with the same quarter of 2025.
    • Net revenues from other products increased to RMB1,051.9 million (US$156.7 million) from RMB622.5 million in the same quarter of 2025. This revenue stream accounted for 5.9% of total net revenues, compared to 4.1% in the same quarter of 2025.
    • Net revenues from others were RMB158.4 million (US$23.7 million), compared to RMB232.9 million in the same quarter of 2025. The decrease was mainly due to lower revenue from delivery for self-operated stores. This revenue stream accounted for 0.9% of total net revenues, compared to 1.4% in the same quarter of 2025.
  • Revenues from partnership stores were RMB4,242.7 million (US$632.2 million), representing an increase of 11.7% from RMB3,798.9 million in the same quarter of 2025. This revenue stream accounted for 23.7% of total net revenues, compared to 24.9% in the same quarter of 2025. Revenues from partnership stores included sales of materials of RMB2,811.2 million (US$418.9 million), delivery service fees of RMB606.3 million (US$90.3 million), profit sharing and royalty fee of RMB580.8 million (US$86.5 million), sales of equipment of RMB214.5 million (US$32.0 million), and franchise and other service fees of RMB30.0 million (US$4.5 million).

Total operating expenses were RMB15,135.5 million (US$2,255.3 million), representing an increase of 12.0% from RMB13,510.6 million in the same quarter of 2025. The increase primarily resulted from the Company’s business expansion. Operating expenses as a percentage of total net revenues decreased to 84.6% from 88.4% in the same quarter of 2025, mainly due to delivery expenses decreasing as a percentage of total net revenues.

  • Cost of materials were RMB6,854.2 million (US$1,021.3 million), representing an increase of 23.7% from RMB5,539.9 million in the same quarter of 2025. The increase was primarily attributable to (i) higher product sales volume and (ii) increased sales of materials to partnership stores.
  • Store rental and other operating costs were RMB3,925.4 million (US$584.9 million), representing an increase of 26.7% from RMB3,097.1 million in the same quarter of 2025. The increase mainly resulted from expanded store footprint and increased items sold which led to year-over-year increases in (i) labor costs, (ii) store rental costs as well as (iii) utilities and other store operating costs.
  • Depreciation and amortization expenses were RMB490.9 million (US$73.2 million), representing an increase of 19.7% from RMB410.0 million in the same quarter of 2025. The increase was mainly due to (i) greater depreciation expenses from new equipment deployed at stores and (ii) higher store leasehold improvement amortization.
  • Delivery expenses were RMB1,789.0 million (US$266.6 million), representing a significant decrease of 38.1% from RMB2,889.2 million in the same quarter of 2025. The decrease was mainly due to a notable shift in order mix from delivery to pick-up.
  • Sales and marketing expenses were RMB976.2 million (US$145.5 million), representing an increase of 30.0% from RMB751.2 million in the same quarter of 2025. The increase was mainly driven by higher spending on advertising and other promotion expenses. Sales and marketing expenses as a percentage of total net revenues was 5.5%, compared to 4.9% in the same quarter of 2025.
  • General and administrative expenses were RMB1,075.3 million (US$160.2 million), representing an increase of 35.5% from RMB793.4 million in the same quarter of 2025. The increase was mainly driven by increases in (i) share-based compensation for management and employees, (ii) payroll costs for general and administrative staff, and (iii) research and development expenses. General and administrative expenses as a percentage of total net revenues was 6.0%, compared to 5.2% in the same quarter of 2025.
  • Store preopening and other expenses were RMB23.4 million (US$3.5 million), representing a decrease of 14.8% from RMB27.4 million in the same quarter of 2025, mainly due to fewer stores preparing to be opened compared to the same quarter of 2025. Store preopening and other expenses as a percentage of total net revenues was 0.1%, compared to 0.2% in the same quarter of 2025.
  • Losses and expenses related to Fabricated Transactions and Restructuring were RMB1.1 million (US$0.2 million), compared to RMB2.3 million in the same quarter of 2025.
  • Store-level operating margin – self-operated stores was 23.3%, improving by 5.8 percentage points from 17.5% in the same quarter of 2025.

GAAP operating income was RMB2,755.9 million (US$410.7 million), representing an increase of 55.1% from RMB1,776.6 million in the same quarter of 2025. GAAP operating margin was 15.4%, an increase of 3.8 percentage points from 11.6% in the same quarter of 2025. Non-GAAP operating income was RMB3,047.0 million (US$454.0 million), representing an increase of 58.2% from RMB1,925.7 million in the same quarter of 2025. Non-GAAP operating margin was 17.0%, an increase of 4.4 percentage points from 12.6% in the same quarter of 2025. For more information on the Company’s non-GAAP financial measures, please see the section “Use of Non-GAAP Financial Measures” and the table captioned “Reconciliation of Non-GAAP Measures to the Most Directly Comparable GAAP Measures” set forth at the end of this press release.

Income tax expenses were RMB914.1 million (US$136.2 million), compared to RMB560.1 million in the same quarter of 2025. The growth was mainly due to higher profits earned in this quarter.

Net income was RMB1,858.9 million (US$277.0 million), representing an increase of 45.4% from RMB1,278.3 million in the same quarter of 2025. Net margin was 10.4%, an increase of 2.0 percentage points from 8.4% in the same quarter of 2025. Non-GAAP net income was RMB2,144.8 million (US$319.6 million), representing an increase of 50.9% from RMB1,421.4 million in the same quarter of 2025. Non-GAAP net margin was 12.0%, an increase of 2.7 percentage points from 9.3% in the same quarter of 2025.

Basic and diluted net income per ADS was RMB5.92 (US$0.88) and RMB5.92 (US$0.88), respectively, compared to RMB4.00 and RMB3.92 in the same quarter of 2025, respectively.

Non-GAAP basic and diluted net income per ADS was RMB6.80 (US$1.04) and RMB6.80 (US$1.04), respectively, compared to RMB4.40 and RMB4.40 in the same quarter of 2025, respectively.

Net cash provided by operating activities was RMB4,131.8 million (US$615.7 million), compared to RMB2,069.2 million in the same quarter of 2025.

Cash and cash equivalents, restricted cash, term deposits and short-term investments were RMB14,333.4 million (US$2,135.8 million) as of September 30, 2026, compared to RMB8,964.4 million as of December 31, 2025.

SHARE REPURCHASE PROGRAM UPDATE AND ADDITIONAL AUTHORIZATION

Pursuant to the Company’s share repurchase program announced in April 2026 and upsized in September 2026, with an aggregate authorized amount of US$500 million (the “Existing Share Repurchase Program”), the Company repurchased a total of 95.8 million Class A ordinary shares (equivalent to 12.0 million American depositary shares (“ADSs”)) for a total consideration of US$391.0 million as of September 30, 2026.

Separately, the Company’s board of directors has approved a new share repurchase program (the “New Share Repurchase Program”), under which the Company may repurchase up to US$500 million of its Class A ordinary shares in the form of ADSs for a 12-month period. The New Share Repurchase Program will commence upon the earlier of (i) the full utilization of the existing US$500 million share repurchase authorization and (ii) the expiration of the term of the Existing Share Repurchase Program.

The Company’s share repurchases, if any, under the New Share Repurchase Program may be made from time to time on the open market at prevailing market prices, in privately negotiated transactions, block trades and/or through other legally permissible means, depending on market and economic conditions and other factors, including share price, applicable legal and regulatory requirements, the Company’s insider trading policy and capital availability. Open-market repurchases may be conducted in reliance on Rule 10b-18 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), where applicable, and repurchases may also be effected pursuant to trading plans intended to satisfy the requirements of Rule 10b5-1 under the Exchange Act.

The New Share Repurchase Program does not obligate the Company to acquire any particular number of ADSs or to expend any particular amount. The Company’s board of directors will review the New Share Repurchase Program periodically and may authorize adjustments to its terms or size, or suspend or terminate the program at any time.

KEY OPERATING DATA

  For the three months ended or as of
  Mar 31,   June 30,   Sep 30,   Dec 31,   Mar 31,   June 30,   Sep 30,
  2025   2025   2025   2025   2026   2026   2026
                           
Total stores 24,097   26,206   29,214   31,048   33,596   36,310   38,909
Self-operated stores 15,598   16,968   18,882   20,234   21,807   23,734   25,402
Partnership stores 8,499   9,238   10,332   10,814   11,789   12,576   13,507
Same-store sales growth for self-operated stores 9.2%   13.8%   14.3%   1.3%   (0.1)%   (5.3)%   (11.1)%
Average monthly transacting customers (in thousands) 74,272   91,697   112,295   98,351   93,089   112,707   123,019
                           

KEY DEFINITIONS

  • GMV (gross merchandise value) refers to the transaction amount from the sales of freshly brewed and non-freshly brewed items through self-operated stores and partnership stores.
  • Total net revenues include revenues from product sales and revenues from partnership stores.
  • Revenues from product sales mainly include net revenue from the sales of freshly brewed and non-freshly brewed items through self-operated stores, e-commerce, offline sales and revenue from delivery for self-operated stores.
  • Revenues from self-operated stores include net revenue from the sales of freshly brewed and non-freshly brewed items through self-operated stores, and delivery fees derived from self-operated stores paid by the Company’s customers.
  • Revenues from partnership stores include net revenue from the sales of materials, equipment, delivery services, profit sharing and royalty fees, franchise and other services from partnership stores.
  • Same-store sales growth for self-operated stores. Defined as the year-over-year growth rate of total revenues from self-operated stores that are identified as qualifying on a monthly basis, meaning stores that were in operation at the beginning of the comparable month and remained open through the end of the current month. Same-store sales growth is calculated by dividing the sum of each current month’s revenue from qualified self-operated stores by the sum of each comparable month’s revenue from those same qualified self-operated stores. Beginning in the first quarter of 2026, we adjusted this definition to better reflect the sales growth of our self-operated stores. Comparative figures from previous periods presented have been adjusted to conform to the updated definition.
  • Store-level operating profit – self-operated stores. Calculated by deducting cost for self-operated stores including cost of direct materials (including wastage in stores), cost of delivery packaging materials, storage and logistics expenses, commissions to third-party delivery platforms related to revenues from self-operated stores, store depreciation expense (including decoration loss for store closure), store rental and other operating costs, delivery expense, transaction fees, store preopening and other expenses from the Company’s self-operated store revenues.
  • Store-level operating margin – self-operated stores. Calculated by dividing store-level operating profit by total revenues from self-operated stores.
  • Total number of stores. The number of stores open at the end of the period.
  • Net new store openings. The number of gross new stores opened during the period minus the number of stores permanently closed during the period.
  • Average monthly transacting customers. The total of each month’s number of transacting customers divided by the number of months during the period (includes those of partnership stores and those only paid with free-coupons).
  • Non-GAAP operating income. Calculated by operating income excluding share-based compensation expenses and deal-related expenses for long-term equity investment.
  • Non-GAAP net income. Calculated by net income excluding recurring item of share-based compensation expenses, one-off item of deal-related expenses for long-term equity investment and income tax effects of GAAP to non-GAAP reconciling items.
  • Non-GAAP net income attributable to the Company’s ordinary shareholders. Calculated by adjusting net income attributable to the Company’s ordinary shareholders excluding recurring item of share-based compensation expenses, one-off item of deal-related expenses for long-term equity investment and income tax effects of GAAP to non-GAAP reconciling items.
  • Non-GAAP basic and diluted net income per share. Calculated as non-GAAP net income attributable to the Company’s ordinary shareholders divided by weighted average number of basic and diluted share.
  • Non-GAAP basic and diluted net income per ADS. Calculated as non-GAAP net income attributable to the Company’s ordinary shareholders divided by weighted average number of basic and diluted ADS.

USE OF NON-GAAP FINANCIAL MEASURES

In evaluating the business, the Company considers and uses non-GAAP operating income/(loss) and non-GAAP net income/(loss), each a non-GAAP financial measure, in reviewing and assessing the Company’s operating performance. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with U.S. GAAP. The Company presents these non-GAAP financial measures because they are used by the Company’s management to evaluate operating performance and formulate business plans. The Company believes that the non-GAAP financial measures help identify underlying trends in the Company’s business, provide further information about the Company’s results of operations and enhance the overall understanding of the Company’s past performance and future prospects.

The non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. The non-GAAP financial measures have limitations as analytical tools. The Company’s non-GAAP financial measures do not reflect all items of income and expense that affect the Company’s operations and do not represent the residual cash flow available for discretionary expenditures. Furthermore, these non-GAAP measures may differ from the non-GAAP information used by other companies, including peer companies, and therefore their comparability may be limited. The Company compensates for these limitations by reconciling the non-GAAP financial measures to the nearest U.S. GAAP performance measure, all of which should be considered when evaluating the Company’s performance. The Company encourages investors and others to review the Company’s financial information in its entirety and not rely on a single financial measure.

The Company defines non-GAAP operating income/(loss) as operating income/(loss) excluding share-based compensation expenses and deal-related expenses for long-term equity investment, non-GAAP net income/(loss) as net income/(loss) excluding recurring item of share-based compensation expenses, one-off item of deal-related expenses for long-term equity investment and income tax effects of GAAP to non-GAAP reconciling items, and non-GAAP net income/(loss) attributable to the Company’s ordinary shareholders as net income/(loss) attributable to the Company’s ordinary shareholders excluding recurring item of share-based compensation expenses, one-off item of deal-related expenses for long-term equity investment and income tax effects of GAAP to non-GAAP reconciling items.

For more information on the non-GAAP financial measures, please see the table captioned “Reconciliation of Non-GAAP Measures to the Most Directly Comparable GAAP Measures” set forth at the end of this earnings release.

EXCHANGE RATE INFORMATION

This earnings release contains translations of certain RMB amounts into U.S. dollars (“US$”) at specified rates solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to US$ were made at the rate of RMB6.7110 to US$1.00, the exchange rate on September 25, 2026 set forth in the H.10 statistical release of the Federal Reserve Board. The Company makes no representation that the RMB or US$ amounts referred could be converted into US$ or RMB, as the case may be, at any particular rate or at all.

CONFERENCE CALL

The Company will host a conference call today, on Tuesday, November 3, 2026, at 8:00 am Eastern Time (or Tuesday, November 3, 2026, at 9:00 pm Beijing Time) to discuss the financial results.

Participants may access the call by dialing the following numbers:

USA/Canada Toll Free: +1-888-317-6003
International: +1-412-317-6061
Mainland China: +86-400-120-6115
Hong Kong: +852-58081995
Conference ID: 5849826
   

The replay will be accessible through November 10, 2026, by dialing the following numbers:

USA/Canada Toll Free: +1-855-669-9658
International: +1-412-317-0088
Access Code: 9066982
   

A live and archived webcast of the conference call will also be available at the Company’s investor relations website at investor.lkcoffee.com.

SAFE HARBOR STATEMENTS

This earnings release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “potential,” “continue,” “ongoing,” “targets,” “guidance” and similar statements. Luckin Coffee may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Any statements that are not historical facts, including statements about Luckin Coffee’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the expense, timing and outcome of existing or future legal and governmental proceedings or investigations in connection with Luckin Coffee; the outcome and effect of the restructuring of Luckin Coffee’s financial obligations; Luckin Coffee’s growth strategies; its future business development, results of operations and financial condition; the effect of the non-reliance identified in, and the resultant restatement of, certain of Luckin Coffee’s previously issued financial results; the effectiveness of its internal control; its ability to retain and attract its customers; its ability to maintain and enhance the recognition and reputation of its brand; its ability to maintain and improve quality control policies and measures; its ability to establish and maintain relationships with its suppliers and business partners; trends and competition in the coffee industry or the food and beverage sector in general; changes in its revenues and certain cost or expense items; the expected growth of China’s coffee industry or China’s food and beverage sector in general; governmental policies and regulations relating to Luckin Coffee’s industry; and general economic and business conditions globally and in China and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks, uncertainties or factors is included in Luckin Coffee’s filings with the SEC. All information provided in this press release and in the attachments is as of the date of this press release, and Luckin Coffee undertakes no obligation to update any forward-looking statement, except as required under applicable law.

STATEMENT REGARDING PRELIMINARY UNAUDITED FINANCIAL INFORMATION

The unaudited financial information set out in this earnings release is preliminary and subject to potential adjustments. Adjustments to the consolidated financial statements may be identified when audit work has been performed for the Company’s year-end audit, which could result in significant differences from this preliminary unaudited financial information. Accordingly, you should not place undue reliance upon these preliminary estimates. The preliminary unaudited financial information included in this press release has been prepared by, and is the responsibility of, the Company’s management. The Company’s auditor has not audited, reviewed, compiled or applied agreed-upon procedures with respect to such preliminary financial data. Accordingly, the Company’s auditor does not express an opinion or any other form of assurance with respect thereto. Upon completion of the year-end audit, the Company’s audited financial results may differ materially from its preliminary estimates.

ABOUT LUCKIN COFFEE INC.

Luckin Coffee Inc. (OTC: LKNCY) has pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. Empowered by proprietary technologies, Luckin Coffee pursues its vision to build a world-class coffee brand and become a part of everyone’s daily life. Luckin Coffee was founded in 2017 and is based in China. For more information, please visit investor.lkcoffee.com.

INVESTOR AND MEDIA CONTACTS

Investor Relations:
Luckin Coffee IR
Email: ir@lkcoffee.com

Bill Zima
ICR
Phone: 646 880 9039

Media Relations:
Luckin Coffee PR
Email: pr@lkcoffee.com

LUCKIN COFFEE INC.
CONSOLIDATED BALANCE SHEET AS OF DECEMBER 31, 2025
AND UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEET AS OF SEPTEMBER 30, 2026
(Amounts in thousands of RMB and US$, except for number of shares)
       
  As of
  December 31, 2025   September 30, 2026
(Unaudited)
  RMB   RMB   US$
ASSETS          
Current assets:          
Cash and cash equivalents 2,294,112   7,586,125   1,130,402
Restricted cash 5,362   114,189   17,015
Term deposit – current 3,328,423   846,306   126,107
Short-term investment, net 2,579,000   5,025,000   748,771
Accounts receivable, net 156,330   198,433   29,568
Receivables from online payment platforms 580,557   798,733   119,018
Inventories, net 2,966,506   2,850,378   424,732
Prepaid expenses and other current assets, net 2,520,657   2,643,249   393,868
Total current assets 14,430,947   20,062,413   2,989,481
           
Non-current assets:          
Long-term investment, net –   644,256   96,000
Property and equipment, net 6,289,986   6,884,123   1,025,797
Restricted cash 57,459   61,782   9,206
Term deposit – non-current 700,000   700,000   104,306
Other non-current assets, net 968,836   1,036,719   154,481
Deferred tax assets, net 217,036   261,122   38,910
Operating lease, right-of-use assets 7,637,320   8,676,659   1,292,901
Total non-current assets 15,870,637   18,264,661   2,721,601
TOTAL ASSETS 30,301,584   38,327,074   5,711,082
           
LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS’ EQUITY          
Current liabilities          
Short-term bank borrowings –   3,250,000   484,280
Accounts payable 1,103,767   1,430,827   213,206
Accrued expenses and other liabilities 4,148,323   5,611,880   836,221
Deferred revenues 156,290   139,553   20,794
Payable for equity litigants settlement 149,887   143,569   21,393
Operating lease liabilities 2,948,353   3,374,458   502,825
Total current liabilities 8,506,620   13,950,287   2,078,719
           
Non-current liabilities:          
Deferred tax liabilities 339,797   533,355   79,475
Operating lease liabilities 4,315,808   4,859,441   724,101
Total non-current liabilities 4,655,605   5,392,796   803,576
Total liabilities 13,162,225   19,343,083   2,882,295
           
Commitments and contingencies          
           
Mezzanine equity          
Convertible senior preferred shares 1,514,660   1,514,660   225,698
           
Shareholders’ equity:          
Class A Ordinary shares 24   24   4
Class B Ordinary shares 2   2   0
Additional paid-in capital 17,278,391   18,002,875   2,682,592
Statutory reserves 453,625   452,759   67,465
Treasury shares –   (2,654,127)   (395,489)
Accumulated earnings/(deficits) (2,438,985)   1,413,317   210,597
Accumulated other comprehensive income 331,642   254,481   37,920
Total Company’s ordinary shareholders’ equity 15,624,699   17,469,331   2,603,089
TOTAL LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS’ EQUITY 30,301,584   38,327,074   5,711,082
           


LUCKIN COFFEE INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
(Amounts in thousands of RMB and US$, except for number of shares and per share data)
               
  For the three months ended September 30,   For the nine months ended September 30,
  2025   2026   2025   2026
  RMB   RMB   US$   RMB   RMB   US$
Net revenues:                      
Revenues from product sales 11,488,260   13,648,725   2,033,784   27,764,284   34,846,795   5,192,490
Revenues from partnership stores 3,798,852   4,242,733   632,206   8,746,978   10,925,768   1,628,039
Total net revenues 15,287,112   17,891,458   2,665,990   36,511,262   45,772,563   6,820,529
                       
Cost of materials (5,539,919)   (6,854,198)   (1,021,338)   (13,675,678)   (17,832,121)   (2,657,148)
Store rental and other operating costs (3,097,088)   (3,925,426)   (584,924)   (8,091,301)   (10,600,680)   (1,579,598)
Depreciation and amortization expenses (409,964)   (490,916)   (73,151)   (1,123,074)   (1,416,033)   (211,002)
Delivery expenses (2,889,182)   (1,788,969)   (266,573)   (5,247,879)   (4,714,737)   (702,539)
Sales and marketing expenses (751,239)   (976,243)   (145,469)   (1,840,153)   (2,633,713)   (392,447)
General and administrative expenses (793,449)   (1,075,277)   (160,226)   (2,210,822)   (2,911,145)   (433,787)
Store preopening and other expenses (27,428)   (23,378)   (3,484)   (59,756)   (65,467)   (9,755)
Impairment loss of long-lived assets –   –   –   (5,509)   (153)   (23)
Losses and expenses related to Fabricated Transactions and Restructuring (2,289)   (1,119)   (167)   (5,596)   (3,790)   (565)
Total operating expenses (13,510,558)   (15,135,526)   (2,255,332)   (32,259,768)   (40,177,839)   (5,986,864)
Operating income 1,776,554   2,755,932   410,658   4,251,494   5,594,724   833,665
                       
Interest and investment income 54,134   41,836   6,234   133,326   120,728   17,990
Interest and financing expenses –   (12,978)   (1,934)   (125)   (14,942)   (2,226)
Foreign exchange loss, net (2,707)   (19,517)   (2,908)   (12,797)   (48,867)   (7,282)
Other income, net 10,476   7,726   1,151   59,824   25,141   3,746
                       
Net income before income taxes 1,838,457   2,772,999   413,201   4,431,722   5,676,784   845,893
Income tax expense (560,133)   (914,118)   (136,212)   (1,349,530)   (1,825,348)   (271,993)
Net income 1,278,324   1,858,881   276,989   3,082,192   3,851,436   573,900
Net income attributable to the Company’s ordinary shareholders 1,278,324   1,858,881   276,989   3,082,192   3,851,436   573,900
                       
Net income per share:                      
Basic 0.50   0.74   0.11   1.20   1.50   0.22
Diluted 0.49   0.74   0.11   1.19   1.50   0.22
Net income per ADS:                      
Basic* 4.00   5.92   0.88   9.60   12.00   1.76
Diluted* 3.92   5.92   0.88   9.52   12.00   1.76
                       
Weighted average shares outstanding used in calculating basic and diluted income per share:                      
Basic 2,564,658,430   2,517,371,654   2,517,371,654   2,564,658,441   2,559,798,522   2,559,798,522
Diluted 2,586,724,800   2,525,722,598   2,525,722,598   2,584,194,116   2,566,517,865   2,566,517,865
                       
Net income 1,278,324   1,858,881   276,989   3,082,192   3,851,436   573,900
Other comprehensive income, net of tax of nil:                      
Foreign currency translation difference, net of tax of nil (17,645)   (3,768)   (561)   (54,739)   (77,161)   (11,498)
Total comprehensive income 1,260,679   1,855,113   276,428   3,027,453   3,774,275   562,402
Total comprehensive income attributable to the Company’s ordinary shareholders 1,260,679   1,855,113   276,428   3,027,453   3,774,275   562,402
                       

* Each ADS represents eight Class A Ordinary Shares. The per ADS indicators are based on rounded results of corresponding per share indicators, which could have a rounding difference of absolute amount for not more than 0.04 per ADS.

LUCKIN COFFEE INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts in thousands of RMB and US$)
               
  For the three months ended September 30,   For the nine months ended September 30,
  2025   2026   2025   2026
  RMB   RMB   US$   RMB   RMB   US$
Net cash provided by operating activities 2,069,201   4,131,760   615,669   5,526,280   7,547,764   1,124,685
Net cash used in investing activities (3,750,368)   (4,142,204)   (617,225)   (7,339,419)   (2,682,901)   (399,776)
Net cash provided by/(used in) financing activities –   (21,045)   (3,136)   (333,600)   595,873   88,791
Effect of foreign exchange rate changes on cash and cash equivalents and restricted cash 2,936   (18,569)   (2,767)   (13,695)   (55,573)   (8,281)
Net increase/(decrease) in cash and cash equivalents and restricted cash (1,678,231)   (50,058)   (7,459)   (2,160,434)   5,405,163   805,419
Cash and cash equivalents and restricted cash at beginning of period 3,924,482   7,812,154   1,164,082   4,406,685   2,356,933   351,204
Cash and cash equivalents and restricted cash at end of period 2,246,251   7,762,096   1,156,623   2,246,251   7,762,096   1,156,623
                       


LUCKIN COFFEE INC.
RECONCILIATION OF NON-GAAP MEASURES TO THE MOST DIRECTLY COMPARABLE GAAP MEASURES
(Unaudited, amounts in thousands of RMB and US$, except for number of shares and per share data)
               
  For the three months ended September 30,   For the nine months ended September 30,
  2025   2026   2025   2026
  RMB   RMB   US$   RMB   RMB   US$
A.     Non-GAAP operating income                      
Operating income 1,776,554   2,755,932   410,658   4,251,494   5,594,724   833,665
Adjusted for:                      
Share-based compensation expenses 149,139   269,473   40,154   430,760   724,484   107,954
Deal-related expenses for long-term equity investment –   21,636   3,224   –   21,636   3,224
Non-GAAP operating income 1,925,693   3,047,041   454,036   4,682,254   6,340,844   944,843
                       
B.     Non-GAAP net income                      
Net income 1,278,324   1,858,881   276,989   3,082,192   3,851,436   573,900
Adjusted for:                      
Share-based compensation expenses 149,139   269,473   40,154   430,760   724,484   107,954
Deal-related expenses for long-term equity investment –   21,636   3,224   –   21,636   3,224
Income tax effects of GAAP to non-GAAP reconciling items (6,030)   (5,165)   (770)   (15,225)   (12,842)   (1,914)
Non-GAAP net income 1,421,433   2,144,825   319,597   3,497,727   4,584,714   683,164
Non-GAAP net income attributable to the Company’s ordinary shareholders 1,421,433   2,144,825   319,597   3,497,727   4,584,714   683,164
                       
C.     Non-GAAP net income per share                      
Weighted average shares outstanding used in calculating basic and diluted income per share:                      
Basic 2,564,658,430   2,517,371,654   2,517,371,654   2,564,658,441   2,559,798,522   2,559,798,522
Diluted 2,586,724,800   2,525,722,598   2,525,722,598   2,584,194,116   2,566,517,865   2,566,517,865
                       
Non-GAAP net income per share:                      
Basic 0.55   0.85   0.13   1.36   1.79   0.27
Diluted 0.55   0.85   0.13   1.35   1.79   0.27
                       
Non-GAAP net income per ADS:                      
Basic* 4.40   6.80   1.04   10.88   14.32   2.16
Diluted* 4.40   6.80   1.04   10.80   14.32   2.16
                       

* Each ADS represents eight Class A Ordinary Shares. The per ADS indicators are based on rounded results of corresponding per share indicators, which could have a rounding difference of absolute amount for not more than 0.04 per ADS.

Internet, Everywhere, Nov. 03, 2026 (GLOBE NEWSWIRE) — Shopify announced today financial results for the quarter ended September 30, 2026. Shopify achieved 32% revenue growth (32% in constant currency) and a 22% free cash flow margin.

“Shopify is uncommonly good at operating in two realities at the same time: the world our merchants exist in today, and the one they are moving towards. Q3 is the perfect example. We powered $119 billion in GMV, while continuing to build commerce into every surface, every agent, and increasingly, everywhere,” said Harley Finkelstein, President of Shopify.

“We extended our track record of consistent execution, with 32% revenue growth and a 22% free cash flow margin,” said Jeff Hoffmeister, Chief Financial Officer of Shopify. “Delivering these results at our scale speaks to the strength of our model, our multiple growth drivers, and our expanding addressable market.”

Selected Business Performance Information(1)
(In US $ millions, except percentages)
  Three months ended
  September 30, 2026     September 30, 2025  
GMV 119,145     92,013  
       
MRR 230     193  
       
Revenue 3,742     2,844  
       
Gross profit 1,781     1,391  
       
Operating income 568     343  
       
Free cash flow 816     507  
       
       
YoY revenue growth rate 32 %   32 %
       
Free cash flow margin 22 %   18 %

(1)  See endnotes below for definitions of GMV and MRR and additional information on constant currency, free cash flow, and free cash flow margin, which are non-GAAP financial measures and are reconciled to the comparable GAAP measures in the non-GAAP reconciliations at the end of this press release. Please refer to the Condensed Consolidated Statements of Cash Flows for additional information on the presentation of cash flows in 2026 and 2025.

2026 Outlook

The outlook that follows supersedes all prior financial outlook statements made by Shopify, constitutes forward-looking information within the meaning of applicable securities laws, is based on a number of assumptions, and is subject to a number of risks. Actual results could vary materially as a result of numerous factors, including certain risk factors, many of which are beyond Shopify’s control. Please see “Forward-looking Statements” at the end of this press release.

For the fourth quarter of 2026, we expect:

  • Revenue to grow at a low-thirties percentage rate on a year-over-year basis;
  • Gross profit dollars to grow at a high-twenties percentage rate on a year-over-year basis;
  • Operating expenses as a percentage of revenue to be 29% to 30%;
  • Stock-based compensation to be $155 million; and
  • Free cash flow margin to be consistent with the fourth quarter of 2025.

Quarterly Conference Call

Shopify’s management team will hold a conference call to discuss its third-quarter results today, November 3, 2026, at 8:30 a.m. ET. The conference call will be webcast in the Investor Relations section of Shopify’s website at www.shopify.com/investors/events. An archived replay of the webcast will be available following the conclusion of the call.

Shopify’s Form 10-Q for the quarter ended September 30, 2026, including the unaudited Condensed Consolidated Financial Statements and accompanying Notes, and Management’s Discussion and Analysis, will be available on Shopify’s website at www.shopify.com and will be filed on EDGAR at www.sec.gov and on SEDAR+ at www.sedarplus.ca.

About Shopify

Shopify provides essential internet infrastructure for commerce. Shopify’s all-in-one platform makes it easier to start, run, and grow a business, powering sales online, in-store, and everywhere in between. Millions of businesses in 175+ countries use Shopify—from entrepreneurs to brands like Aldo, BarkBox, Carrier, Meta, SKIMS, Supreme, and Vuori.

For more information, visit www.shopify.com.

CONTACT INVESTORS: Shane Kleinstein   CONTACT MEDIA: Jackie Warren
  Director, Investor Relations     Senior Lead, Communications
  IR@shopify.com     press@shopify.com

Shopify Inc. Condensed Consolidated Statements of Operations
(In US $ millions)
  Three months ended
  September 30, 2026     September 30, 2025  
Revenues      
Subscription solutions 836     699  
Merchant solutions 2,906     2,145  
  3,742     2,844  
Cost of revenues      
Subscription solutions 175     128  
Merchant solutions 1,786     1,325  
  1,961     1,453  
Gross profit 1,781     1,391  
Operating expenses      
Sales and marketing 466     410  
Research and development 497     375  
General and administrative 130     115  
Transaction and loan losses 120     148  
Total operating expenses 1,213     1,048  
Operating income 568     343  
Net other expense, including taxes(2) (106 )   (79 )
Net Income 462     264  
less: equity investments, marked to market, net of taxes (122 )   (103 )
Net income excluding the impact of equity investments(3) 584     367  
 
(2) Net other expense, including taxes includes interest income, gains and losses on equity and other investments, loss on embedded derivative related to convertible note, foreign exchange gains and losses, and our provision for income taxes.
(3) Net income excluding the impact of equity investments is a non-GAAP financial measure which is reconciled at the end of this press release. This measure excludes the impact of any gains or losses on our equity investments in third parties and embedded derivative related to convertible note. Shopify believes this measure provides useful information to investors given that valuations of third parties in public and private markets are outside of our control, and therefore, fluctuations in those valuations are not relevant to the fundamentals of our business and have little analytical or predictive value regarding our ability to drive operational results. This measure does not have a standardized meaning under US GAAP and may not be comparable to similar measures presented by other companies.

Note: More detailed Condensed Consolidated Statements of Operations and Comprehensive Income are available in the Quarterly Report on Form 10-Q filed concurrently with this press release with US and Canadian regulators and available on www.sec.gov and www.sedarplus.ca.

Shopify Inc. Condensed Consolidated Balance Sheets
(In US $ millions)

  September 30, 2026   December 31, 2025
Assets      
Current assets      
Cash and cash equivalents  1,868     1,545 
Marketable securities  2,859     4,233 
Trade and other receivables, net  483     500 
Loans and merchant cash advances, net  2,350     1,784 
Other current assets  226     234 
   7,786     8,296 
Long-term assets      
Long-term assets(4)  327     210 
Deferred tax assets  83     33 
Long-term investments  524     975 
Equity and other investments  4,911     4,582 
Equity method investment  538     602 
Goodwill  495     491 
   6,878     6,893 
Total assets  14,664     15,189 
Liabilities and shareholders’ equity      
Liabilities      
Accounts payable  630     570 
Deferred tax liabilities  63     55 
Other liabilities(5)  1,222     1,091 
   1,915     1,716 
Shareholders’ equity  12,749     13,473 
Total liabilities and shareholders’ equity  14,664     15,189 
       
(4) Long-term assets includes Property and equipment, net, Operating lease right-of-use assets, net, Intangible assets, net, and Other long-term assets.
(5) Other liabilities includes Accrued liabilities, Current and Long-term Deferred revenue, and Operating lease liabilities.
Note: More detailed Condensed Consolidated Balance Sheet and Notes to the Condensed Consolidated Financial Statements are available in the Quarterly Report on Form 10-Q filed concurrently with this press release with US and Canadian regulators and available on www.sec.gov and www.sedarplus.ca.

Shopify Inc. Condensed Consolidated Statements of Cash Flows
(In US $ millions)
  Three months ended
  September 30, 2026   September 30, 2025
Cash flows from operating activities      
Net income for the period 462     264  
Adjustments to reconcile net income to
net cash provided by operating activities:
     
Amortization and depreciation 7     8  
Stock-based compensation 140     107  
Impairment of right-of-use assets and leasehold improvements —     3  
Provision for transaction and loan losses 67     102  
Deferred income tax recovery (68 )   (5 )
Revenue related to non-cash consideration (13 )   (12 )
Unrealized loss on embedded derivative —     29  
Net loss on equity and other investments 117     62  
Net loss on equity method investment 21     21  
Unrealized foreign exchange loss 1     4  
Changes in operating assets and liabilities 84     (70 )
Net cash provided by operating activities 818     513  
Cash flows from investing activities      
Purchases of property and equipment (2 )   (6 )
Purchases of marketable securities (866 )   (1,460 )
Maturities of marketable securities 1,302     1,956  
Purchases and originations of loans and merchant cash advances(6) (1,700 )   (996 )
Repayments and sales of loans and merchant cash advances(6) 1,471     849  
Purchases of equity and other investments (161 )   (8 )
Acquisition of business, net of cash acquired (5 )   —  
Acquisition of intangible assets (99 )   —  
Net cash (used in) provided by investing activities (60 )   335  
Cash flows from financing activities      
Proceeds from the exercise of stock options 15     24  
Repurchases of common stock (562 )   —  
Net cash (used in) provided by financing activities (547 )   24  
Effect of foreign exchange on cash,
cash equivalents and restricted cash
1     —  
Net increase in cash, cash
equivalents and restricted cash
212     872  
Cash, cash equivalents and restricted cash – beginning of period 1,656     1,542  
Cash, cash equivalents and restricted cash – end of period 1,868     2,414  
(6) Starting in April 2026, the cash flows associated with merchant cash advances are presented within investing cash flows rather than operating cash flows on a basis consistent with loans, given the similar nature of the underlying lending activities. For the three months ended September 30, 2026, the changes described above resulted in a net cash use of $30 million presented in investing activities after consideration of repayments and purchases and originations.


Reconciliation of Non-GAAP Financial Measures

Free Cash Flow Reconciliation
(In US $ millions, except percentages)

The following table illustrates how free cash flow is calculated in this press release:

  Three months ended
  September 30, 2026     September 30, 2025  
Net cash provided by operating
activities
818     513  
less: capital expenditures(7) (2 )   (6 )
Free cash flow 816     507  
Revenue 3,742     2,844  
Free cash flow margin 22 %   18 %
(7) Capital expenditures is equivalent to the amount included in “Purchases of property and equipment” on our Condensed Consolidated Statements of Cash Flows for the reported period.


Net Income Excluding the Impact of Equity Investments Reconciliation
(In US $ millions)

The following table illustrates how Net income excluding the impact of equity investments is calculated in this press release:

  Three months ended
  September 30, 2026     September 30, 2025  
Net Income  462      264  
less: equity investments,
marked to market, net of taxes
 (122 )    (103 )
Net income
excluding the impact of equity investments(3)
 584      367  


Reconciliation of GAAP Net Income to Non-GAAP Net Income
(In US $ millions, except share and per share amounts)
The following table reconciles GAAP net income to Non-GAAP net income and includes net income per share amounts:
 
  Three months ended
  September 30, 2026   September 30, 2025
GAAP net income   462       264  
Non-GAAP adjustments to net income:      
Stock-based compensation expense and related taxes   147       116  
Amortization of acquired intangible assets   2       3  
Impairment of right-of-use assets and leaseholds   —       3  
Non-GAAP operating income adjustments   149       122  
Net loss on equity and other investments   117       62  
Net loss on equity method investment   21       21  
Loss on embedded derivative   —       29  
Income tax effects and tax adjustments   (111 )     (57 )
Non-GAAP net income   638       441  
       
Diluted net income per share attributable to shareholders(8):      
GAAP $ 0.36     $ 0.20  
Non-GAAP $ 0.49     $ 0.34  
       
Weighted average shares used to compute net income per share attributable to shareholders:      
Diluted   1,290,726,742       1,312,872,709  
(8) May include rounding


Constant Currency Analysis
(In US $ millions, except percentages)

The following table converts our GMV, revenues, gross profit, and operating income using the comparative period’s monthly average exchange rates. We have provided the below disclosure as we believe it presents a clear comparison of our period-to-period operating results by removing the impact of fluctuations in foreign exchange rates and to assist investors in understanding our financial and operating performance. The table below and our Condensed Consolidated Statements of Operations disclosure are supplements to our Condensed Consolidated Financial Statements, which are prepared and presented in accordance with US GAAP (excluding GMV).

  Three months ended September 30,
  GMV   Revenue   Subscription
solutions
revenue
  Merchant
solutions
revenue
  Gross
profit
  Operating
income
2025 as reported 92,013     2,844     699     2,145     1,391     343  
2026 as reported 119,145     3,742     836     2,906     1,781     568  
Percentage change YoY 29 %   32 %   20 %   35 %   28 %   66 %
Constant currency impact (25 )   (4 )   (1 )   (3 )   (1 )   2  
Percentage change YoY
constant currency
30 %   32 %   20 %   36 %   28 %   65 %


Regulatory Disclosures and Forward-looking Statements

Advisory Regarding Forward-looking Statements

This press release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”), including statements related to Shopify’s financial outlook, such as expected revenue and expenses for the next fiscal quarter, Shopify’s expectations regarding future investments in the business, and Shopify’s expectations regarding the development of emerging technologies, including AI. These statements can be identified by words such as “will” and “expect” and are based on Shopify’s current projections and expectations about future events and financial results. Known and unknown risks may cause actual results to differ materially from those described in the forward-looking statements. These risks include, but are not limited to, the Company’s ability to maintain expected growth and manage expenses, the impact of changes in economic conditions and consumer spending in key markets such as the United States, Europe, and globally, the impact of measures that affect international trade, including tariffs, the adoption and impact of emerging technologies such as AI, our reliance on third-party providers to deliver services, a cyberattack or security breach, and serious errors or defects in software or hardware. Other factors and risks that may cause actual results to differ materially from those set out in the forward-looking statements are set out in Shopify’s Form 10-Q under the heading “Risk Factors” and other filings made with US and Canadian securities regulators, available at www.sec.gov and www.sedarplus.ca. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to management on the date hereof and represent management’s beliefs regarding future events, projections, and financial trends, which, by their nature, are inherently uncertain. The forward-looking statements are provided to give additional information about management’s expectations and beliefs and may not be appropriate for other purposes. Shopify undertakes no duty to publicly update or revise any forward-looking statements, except as may be required by law.

Endnotes:

Gross Merchandise Volume, or GMV, represents the total dollar value of orders facilitated through the Shopify platform including certain apps and channels for which a revenue-sharing arrangement is in place in the period, net of refunds, and inclusive of shipping and handling, duty, and value-added taxes.

Monthly Recurring Revenue, or MRR, is the aggregate value of all subscription plans, excluding variable platform fees, in effect on the last day of the period, assuming merchants maintain their subscription the following month and is used by management as a directional indicator of subscription solutions revenue going forward.

Free cash flow and free cash flow margin are non-GAAP financial measures that are reconciled in the non-GAAP reconciliation within this press release. These non-GAAP financial measures do not have standardized meanings under US GAAP and may not be comparable to similar measures presented by other companies. Shopify believes free cash flow and free cash flow margin provide useful information to help investors and others understand our operating results and the performance of our business in the same manner as management. Shopify does not reconcile forward-looking non-GAAP free cash flow margin because certain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably estimated. Free cash flow is a non-GAAP financial measure calculated as cash flow from operations less capital expenditures.

Reconciliation of GAAP Net Income to Non-GAAP Net Income provides supplementary non-GAAP financial measures for non-GAAP net income and diluted net income per share to consider in evaluating operating performance. Non-GAAP adjustments to net income include stock-based compensation expense and related payroll taxes, amortization of acquired intangible assets, impairment of right-of-use assets and leaseholds, net loss on equity and other investments, net loss on equity method investment, loss on embedded derivative, and income tax effects and tax adjustments, including a release of valuation allowance as a discrete tax benefit. These non-GAAP measures should not be viewed as a substitute for reported results determined in accordance with GAAP, nor are they necessarily comparable to non-GAAP measures that may be presented by other companies.

  • With a goal of providing multiple data sets demonstrating differentiated efficacy and safety in multiple ANCA-associated vasculitis (AAV) settings, InflaRx intends to begin two Phase 2 trials in 2027, with first data readout anticipated in 2028
  • Phase 2 AAV izicopan program expected to include a placebo-controlled randomized study in patients with renal involvement with site initiation in early 2027, as well as an open-label “all-comers” study to demonstrate the ability to replace corticosteroids
  • Initial data from an investigator-initiated open-label pilot study in atypical hemolytic uremic syndrome (aHUS) anticipated in the second half of 2027
  • InflaRx planning pilot study in IgA nephropathy (IgAN) to be initiated in 2027, with expected early data readout in 2028
  • InflaRx announces Advisory Board comprised of leading international experts in vasculitis, nephrology and immune-mediated renal disease
  • InflaRx proprietary research indicates izicopan’s product profile supports the potential for significant AAV market expansion, with an estimated peak sales potential in the range of $1.5 – 2.0 billion
  • BDB-001, a vilobelimab cell line-produced antibody targeting C5a and being evaluated by InflaRx’s collaborator, Staidson BioPharmaceuticals Co., Ltd. (Staidson), is currently in a Phase 3 trial in AAV in China, with data anticipated in 2H 2028
  • Cash, cash equivalents and marketable securities totaled €153.3 million on September 30, 2026, expected to fund ongoing operations and clinical development through 2029

Jena, Germany, Nov. 03, 2026 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today is presenting its clinical development strategy and commercial vision for izicopan at the Company’s Capital Markets Day.

InflaRx is executing an AAV program with the goal of enabling rapid study starts and the generation of differentiating efficacy and safety data sets, which will allow the Company to continue discussions with the FDA. InflaRx expects trial site initiation to begin in early 2027 for a randomized, placebo-controlled Phase 2 study in patients with AAV with renal involvement (i.e., renal vasculitis) to assess izicopan’s ability to drive meaningful signals of clinical efficacy. The trial design has been optimized to demonstrate potential benefits related to renal function and renal injury recovery when tested in comparison to placebo, both on top of standard of care. The trial is expected to be conducted internationally, with a currently planned enrollment period of approximately 18 months.

In addition, InflaRx intends to initiate an open-label Phase 2 trial in 2027 in newly diagnosed or relapsing AAV patients in need of remission induction therapy, exploring safety and efficacy in patients when replacing glucocorticoid (GC) treatment. First data from this open-label study are expected in 2028. Given their different enrollment criteria and planned separate center selection, InflaRx does not expect the concurrent running of these studies to negatively impact speed of enrollment.

“Our Capital Markets Day underscores our conviction that izicopan has the potential to become a differentiated therapy for patients with ANCA-associated vasculitis and other renal diseases,” said Prof. Dr. Niels Riedemann, Chief Executive Officer and Founder of InflaRx. “C5aR inhibition has been clinically and commercially validated, and izicopan was specifically optimized to build on that foundation. Its rapid and sustained target inhibition, improved metabolic profile and potential for more convenient dosing support a compelling product profile. Combined with our focused development strategy, we believe izicopan is well positioned to address important unmet needs in AAV and potentially establish a broader renal-disease franchise. We have benefited from the expert guidance of the distinguished clinicians and researchers who now comprise our AAV and renal disease Advisory Board, and we look forward to continuing to work closely with them as we advance izicopan in AAV and explore its potential across additional renal diseases.”

AAV development path

To leverage the strengths of izicopan’s pharmacologic properties against the substantial unmet need that exists in AAV, InflaRx’s izicopan AAV program is targeting the generation of multiple differentiating efficacy and safety data sets in a variety of AAV settings with different strategic goals.

InflaRx expects trial site initiation to begin in early 2027 in a randomized, double-blind, placebo-controlled Phase 2 trial evaluating two izicopan doses on top of standard of care, including rituximab and GC tapering. The current design contemplates approximately 35 patients per arm and 12 months of treatment, with key data readouts occurring at 24 weeks. Efficacy assessments are expected to include disease remission, renal function, proteinuria, hematuria and renal recovery endpoints alongside safety and other efficacy assessments, as well as GC use. The enrollment period is expected to be approximately 18 months. The trial design will focus on AAV patients with defined renal involvement (renal vasculitis) and has been optimized to detect potential efficacy signals of izicopan on renal function and renal injury recovery when compared to placebo treatment.

In addition, InflaRx intends to initiate an open-label Phase 2 trial in 2027 in newly diagnosed or relapsing AAV patients in need of remission induction therapy, exploring safety and efficacy in patients when replacing GC treatment. For this, a two-stage design is planned in which a rapid taper of GC is applied in Stage 1, during remission induction therapy (e.g., in conjunction with rituximab). Upon safety assessment, a planned complete replacement strategy will be explored in Stage 2. First data from this study are expected in 2028. The trial will assess the ability of izicopan to replace GC treatment during remission induction without impacting patient safety.

This open-label trial is informed by a recently conducted Phase 1/2 trial with BDB-001, a vilobelimab cell line-produced antibody targeting C5a licensed to the Company’s Chinese partner, Staidson, in which a complete GC replacement at enrollment was successfully conducted and yielded numerically favorable remission rates when compared to the open-label control arm. The trial is further supported by external market research indicating the value that physicians ascribe to data demonstrating the ability to minimize GC use in AAV.

As currently planned, the randomized placebo-controlled Phase 2 study has been informed by first interactions with the FDA and is designed to evaluate efficacy signals focusing on renal and disease activity endpoints. InflaRx continues to evaluate options to transition as quickly as possible into registrational phase.

InflaRx continues to anticipate engaging with EMA regarding both vilobelimab and izicopan to likewise evaluate the regulatory path for InflaRx to the AAV market in that geography.

In addition, BDB-001, a vilobelimab cell line-produced antibody targeting C5a which is being evaluated by InflaRx’s collaborator Staidson, is currently in a Phase 3 trial in AAV in China, with data anticipated in 2H 2028.

Izicopan commercial potential

C5aR inhibition is an established therapeutic approach in AAV, while persistent limitations in the current standard of care create an opportunity for a next-generation therapy such as izicopan, which InflaRx believes has the potential to provide faster and deeper target inhibition, an improved safety profile (with no safety signals of concern observed to date in the 197 human subjects dosed with izicopan) and more convenient dosing. InflaRx believes izicopan has the potential to serve a greater proportion of AAV patients and to significantly expand the commercial market, with an estimated peak sales potential in the range of $1.5 – 2.0 billion, based on an independent commercial assessment.

Izicopan in broader renal disease

In addition to its efforts in AAV, InflaRx anticipates multiple proof-of-concept studies with izicopan in rare renal diseases. The Company believes izicopan’s improved pharmacologic properties are applicable to the considerable unmet needs in these areas as well, including the potential for once-daily oral dosing, lack of membrane attack complex (MAC) inhibition, and lack of vaccine requirement.

Efforts in broader renal disease include the initiation of an investigator-initiated trial (IIT) in aHUS that is expected to provide initial select patient data in 2H 2027. In addition, the Company plans to initiate a pilot study in patients with IgAN and rapidly progressive IgAN (rapidly progressive glomerulonephritis (RPGN) in IgAN patients), with initial data from patients targeted for 2028. Signal finding studies in additional rare renal disorders are contemplated as well.

To facilitate enrollment in China, a pharmacokinetic (PK) bridging study with izicopan in China is expected to have data in the first half of 2027.

AAV and renal disease advisory board

InflaRx has formed an AAV and renal disease Advisory Board, comprised of internationally recognized experts across vasculitis, nephrology, autoimmunity and immune-mediated kidney disease who have been advising the Company on its recent efforts, covering the scientific, clinical and development considerations relevant to its programs in AAV and select renal diseases. The Advisory Board is expected to provide independent expert perspectives on disease biology, patient care, clinical development and the evolving treatment landscape. Its input will help inform InflaRx’s efforts to advance complement-targeted therapeutic candidates for patients with serious inflammatory and renal diseases.

Current members of the Advisory Board include:

Professor Jonathan Barratt, PhD, FRCP
Prof. Dr. med. Jürgen Floege
Prof. Dr. med. Bernhard Hellmich
David Jayne, MD, FMedSci
Prof. Dr. med. Andreas Kronbichler
Peter A. Merkel, MD, MPH
Prof. Dr. Ming-Hui Zhao

Additional information related to the Advisory Board members, including affiliations and biographies, can be found on the InflaRx website.

InflaRx financial position

With a strong intellectual property position and an expected cash runway through 2029, InflaRx believes it is positioned to advance izicopan in AAV while selectively expanding its renal-development portfolio.

About izicopan
Izicopan is an orally administered, small molecule inhibitor of the C5a receptor (C5aR) that has shown anti-inflammatory therapeutic effects in several pre-clinical disease models and in human studies. InflaRx is planning for development of izicopan in ANCA-associated vasculitis (AAV) and additional renal indications.

In contrast to the marketed C5aR inhibitor, in vitro experiments demonstrated that izicopan does not exhibit time-dependent inhibition of cytochrome P450 3A4 (CYP3A4/5), which plays an important role in the metabolism of a variety of metabolites and drugs, including glucocorticoids. Izicopan has also demonstrated a favorable reactive metabolite profile in human liver microsomes. Reported results from a first-in-human study demonstrated that izicopan was well tolerated in treated subjects and exhibited no safety signals of concern in single doses ranging from 3 mg to 240 mg or multiple doses ranging from 30 mg once per day to 90 mg twice per day for 14 days. Pharmacokinetic / pharmacodynamic data support the best-in-class potential of izicopan, with a ≥90% blockade of C5a-induced neutrophil activation achieved over the 14-day dosing period. Topline Phase 2a data further support the safety profile of izicopan, with no reported safety signals of concern. In patients with hidradenitis suppurativa, over 4 weeks of therapy, izicopan provided rapid and clinically meaningful reductions in abscesses and nodules and draining tunnels, robust HiSCR responses that continued to deepen four weeks after the treatment period, and substantial reductions in patient-reported pain scores, overall demonstrating the potential for biologic-like efficacy. In chronic spontaneous urticaria, InflaRx observed substantial reductions in the 7-day Urticaria Activity Score (UAS7) broadly across patients and particularly in those with severe disease, as well as improved disease control as measured by the Urticaria Control Test (UCT7).

About InflaRx
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx‘s lead program is izicopan, an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor, which has shown promising PK/PD characteristics as well as therapeutic potential in Phase 1 and Phase 2a clinical studies. The Company is developing izicopan for the treatment of ANCA-associated vasculitis and additional renal diseases. InflaRx also has developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies.

InflaRx has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de. Follow InflaRx on LinkedIn. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).

Contacts:

InflaRx N.V. MC Services AG
Jan Medina, CFA
Vice President, Head of Investor Relations
Email: IR@inflarx.de
Katja Arnold, Laurie Doyle, Dr. Regina Lutz
Email: inflarx@mc-services.eu
Europe: +49 89-210 2280
U.S.: +1-339-832-0752

FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, the therapeutic potential of izicopan in renal and other complement-mediated diseases; the success of our future clinical trials for izicopan’s treatment of AAV and other renal diseases, including aHUS, IgAN and C3G, as well as our assessment of a broader development and registrational strategy in Europe following the revocation of the marketing authorization for Tavneos (avacopan) in the European Union, the United Kingdom and other jurisdictions, and our ability to establish proof of concept for izicopan across such indications; the timing of initiation, enrollment and data readouts of our planned Phase 2 trials of izicopan in AAV, the investigator-initiated trial in aHUS, our planned pilot study in IgAN and our PK bridging study in China; the timing, progress and results of the Phase 3 trial of BDB-001 being conducted by our collaborator Staidson in China; the timing, progress and results of preclinical studies and clinical trials of vilobelimab, izicopan and any other of our product candidates; our interactions with regulators regarding the results of clinical trials and potential regulatory approval pathways, including potential regulatory paths in AAV for vilobelimab and izicopan and related discussions with the FDA and EMA; the timing and outcome of any discussions or submission of filings for regulatory approval of vilobelimab, izicopan or any other product candidate, and the timing of and our ability to obtain and maintain full regulatory approval and/or marketing authorization for any indication; potential strategic transactions or collaborations, including a potential partnership of izicopan or vilobelimab for PG, HS, CSU or any other indications; our expectations regarding the size of the patient populations for, the market opportunity for and the potential peak sales of izicopan, if approved; whether the FDA, EMA or any comparable foreign regulatory authority will accept or agree with the number, design, size, conduct or implementation of our clinical trials, including any proposed primary or secondary endpoints for such trials; whether the results of our future clinical trials will reflect results seen in previously conducted preclinical studies and clinical trials, and the limitations of cross-study comparisons of izicopan to other product candidates or approved products, including avacopan; our ability to leverage our proprietary anti-C5a and anti-C5aR technologies to discover and develop therapies to treat complement-mediated immunological and inflammatory diseases; our ability to protect, maintain and enforce our intellectual property protection for vilobelimab, izicopan and any other product candidates, and the scope of such protection; our manufacturing capabilities and strategy, including the scalability and cost of our manufacturing methods and processes, the optimization of our manufacturing methods and processes, and our ability to rely on existing third-party manufacturers or engage additional third-party manufacturers for planned future clinical trials and commercial supply; our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for or ability to obtain additional financing, and the period through which our existing cash, cash equivalents and marketable securities will be sufficient to fund our operations; our ability to defend against liability claims resulting from the testing of our product candidates in the clinic or, if approved or authorized, any commercial sales; if any of our product candidates obtain regulatory approval or authorization, our ability to comply with and satisfy ongoing drug regulatory obligations and continued regulatory oversight; our ability to comply with enacted and future legislation in seeking marketing approval, authorization or commercialization; our future growth and ability to compete, which depends on our retaining key personnel and recruiting additional qualified personnel; our competitive position and the development of and projections relating to our competitors in the development of C5a and C5aR inhibitors (including avacopan) and other therapeutic products being developed in similar medical conditions in which vilobelimab, izicopan or any other of our product candidates is being developed or our industry; risks related to our reliance on foreign third-party manufacturers and suppliers, including those located in China; and the risks, uncertainties and other factors described under the heading “Risk Factors” in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

Peer-reviewed publication reports a 77% relative risk reduction in bloodstream infections and significantly lower systemic antibiotic exposure with SER-155 compared with placebo

Translational data from the study support the SER-155 mechanisms of strengthening the mucosal epithelial barrier and reducing systemic inflammation

CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) — Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that results from its Phase 1b clinical study of SER-155 in adults undergoing allogeneic hematopoietic cell transplantation (allo-HCT) have been published in the November 3, 2026 issue of Nature Medicine. SER-155 is an investigational, oral, cultivated multi-strain live biotherapeutic product (LBP) designed to reduce the risk of bloodstream infections (BSIs) in medically vulnerable patients. The publication reports that SER-155 was generally well tolerated and was associated with a 77% relative risk reduction in BSIs compared with placebo. SER-155 has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the reduction of BSIs in adults undergoing allo-HCT, as well as Fast Track designation, and the Company has aligned with the FDA on its proposed Phase 2 study protocol. SER-155 is Phase 2-ready in allo-HCT, pending receipt of funding.

“Publication in Nature Medicine is an important milestone for the SER-155 program and recognition of the innovative science being advanced by Seres,” said Matthew Henn, Ph.D., President and Chief Scientific Officer of Seres Therapeutics. “Many bloodstream infections in transplant patients originate in the gut, when pathogens expand and cross a damaged intestinal barrier. SER-155 was designed to address both sides of that problem by preventing the colonization and expansion of pathogens, many that can harbor antibiotic resistance, in the gastrointestinal tract that results from extensive antibiotic use in these patients and also protecting and improving mucosal epithelial barrier integrity that is disrupted by conditioning cancer therapy to limit bacterial translocation from the GI into the bloodstream and potential mortality due to infection. In this study, SER-155 reduced bloodstream infections while improving biomarkers of barrier integrity and systemic inflammation, providing clinical validation of these mechanisms. We believe our live biotherapeutic approach could be highly differentiated in multiple diseases where loss of gut mucosal epithelial barrier integrity is thought to play a central role. In addition, SER-155 has the potential to address the continued emergence of antimicrobial resistant infections, particularly those in immunocompromised patients, and we thank CARB-X for their prior support of this program, our collaborators and the patients who participated in this clinical study.”

The Phase 1b study (NCT04995653) evaluated SER-155 in adults undergoing allo-HCT for hematologic malignancies. Cohort 1 was an open-label cohort that assessed safety and drug pharmacology, including engraftment of SER-155 strains in the gastrointestinal (GI) tract. Cohort 2 was a randomized, double-blind, placebo-controlled cohort that evaluated safety, drug pharmacology and clinical outcomes, including BSIs, systemic antibiotic exposure and febrile neutropenia, through day 100 after transplant.

In Cohort 2, BSIs occurred in 10% of patients receiving SER-155 compared with 42.9% of patients receiving placebo, a 77% relative risk reduction (p=0.0423). Patients receiving SER-155 also had significantly lower systemic antibiotic exposure, with a mean of 9.2 days compared with 21.1 days for placebo (p=0.0494), and a numerically lower incidence of febrile neutropenia (65% compared with 78.6%). SER-155 strains engrafted in the GI tract, and SER-155 was generally well tolerated, with no treatment-related serious adverse events observed.

Translational biomarker analyses from the study further support SER-155 mechanisms of action. Compared with placebo, SER-155 led to a statistically significant decrease in fecal albumin, an established biomarker of epithelial barrier integrity, and lower plasma levels of biomarkers of systemic inflammation. SER-155 also improved biomarkers of immune homeostasis. Improved mucosal epithelial barrier integrity may reduce bacterial translocation from the GI tract into the bloodstream, consistent with the reduction in BSIs observed in the study. These barrier-protective and anti-inflammatory effects also support the potential of Seres’ LBPs in inflammatory and immune diseases, including immune checkpoint inhibitor related enterocolitis (irEC) and inflammatory bowel disease (IBD).

“These results, now peer-reviewed and published in Nature Medicine, reinforce our belief in the potential of SER-155 to prevent bloodstream infections in immunocompromised patients like allo-HCT patients,” said Richard Kender, Executive Chairman and Interim Chief Executive Officer of Seres Therapeutics. “We believe the ability of SER-155 to strengthen the gut barrier and reduce inflammation gives it potential well beyond transplant, including in immune checkpoint inhibitor-related enterocolitis (irEC), a serious complication of cancer immunotherapy where an immunosuppressive-free treatment could allow patients to stay on their cancer therapy.”

Seres is also developing SER-155 for irEC, a frequent and often severe adverse reaction that can force patients to interrupt or discontinue immune checkpoint inhibitor (ICI) cancer therapy and initiate immunosuppressive therapy. In July 2026, Seres reported results from an open-label investigator-sponsored trial at Memorial Sloan Kettering Cancer Center in 15 patients with Grade 2-3 irEC who had not received immunosuppressive therapy. Twelve of 15 participants (80%) achieved an immunosuppressive-free clinical response at day 15, the study’s primary endpoint, and SER-155 was generally well tolerated, with no serious adverse events assessed as related to SER-155. In the irEC study, fecal calprotectin and fecal albumin, markers of gut inflammation and mucosal barrier integrity, decreased significantly from baseline by day 43, consistent with the barrier-protective activity observed in allo-HCT.

Publication Details
Journal: Nature Medicine
Title: A live biotherapeutic product for adult allogeneic hematopoietic cell transplantation recipients: a partially randomized, placebo-controlled phase 1b trial
Publication Date & Access: November 3, 2026
Authors: Doris M. Ponce*, Zachariah DeFilipp*, Christopher B. Ford, Bina Tejura, Mary-Jane Lombardo, David I. Lichter, Meghan Chafee, Satyajit Kosuri, Nandita Khera, Hemant S. Murthy, Karamjeet S. Sandhu, David N. Fredricks, Tessa Andermann, Rajneesh Nath, Kelly Brady, Brooke R. Hasson, Emily Walsh, Nathan Hicks, Jonathan U. Peled, Lisa von Moltke, Matthew R. Henn, Marcel R.M. van den Brink**, Dennis M. Walling** and the SER-155-001 Study Team***. *These authors contributed equally. **These authors jointly supervised this work. ***A list of consortium authors and their affiliations appears at the end of the paper.

About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage biotechnology company developing novel live biotherapeutics products in oncology that address causes of mortality and discontinuation of life-saving cancer treatment, and in inflammatory and immune (I&I) diseases, by modulating host function to protect and improve mucosal epithelial barrier integrity, induce immune homeostasis and tolerance, and prevent the colonization and overgrowth of pathogens in the gastrointestinal (GI) tract. The Company previously led the development and FDA approval of VOWST™, the first orally administered microbiome therapeutic, which was subsequently divested to Nestlé Health Science. SER-155, an investigational cultivated multi-strain biotherapeutic, which has received Breakthrough Therapy and Fast Track designations, is being advanced for the prevention of bloodstream infections in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HCT), and is Phase 2 ready, pending receipt of funding. SER-155 is also being developed to prevent immune checkpoint inhibitor-related enterocolitis (irEC), with the aim of enabling patients to continue their ICI cancer therapy and avoid the need for immunosuppressive steroid treatment. Following promising results from an investigator-sponsored trial, Seres plans to submit the design of a study for the prevention of irEC in patients initiating ICI therapy to the FDA. The Company is advancing IND-enabling studies for SER-603, which is in development for inflammatory bowel disease. Mechanistically, Seres’ biotherapeutics target the mucosal epithelial barrier-immune interface and are optimized to modulate host function to increase mucosal epithelium integrity, induce immune homeostasis, and prevent the colonization and overgrowth of harmful bacteria in the GI tract. For more information, please visit www.serestherapeutics.com. 

About CARB-X
CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) is the world’s leading non-profit partnership accelerating the research and development of innovative products to prevent, diagnose and treat bacterial infections and address the global threat of antimicrobial resistance. CARB-X pairs non-dilutive funding with comprehensive technical and scientific support, resulting in supported projects being five times more likely to advance into clinical development than comparable projects that did not receive CARB-X support. Research reported in this press release is partially supported by CARB-X. CARB-X is funded in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA) under agreement number 75A50122C00028 and by awards from Wellcome (WT224842), the UK Department of Health and Social Care’s Global Antimicrobial Resistance Innovation Fund (GAMRIF), the Gates Foundation, Germany’s Federal Ministry of Research, Technology and Space (BMFTR), the Novo Nordisk Foundation, Italy’s Ministry of Economy and Finance (MEF), Japan’s Ministry of Health, the European Commission’s DG Health Emergency Preparedness and Response Authority (DG HERA), and KfW Development Bank. The U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) in HHS, provides support in the form of in-kind services through access to a suite of preclinical services for product development. The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or its funders

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements about: SER-155 and its intended uses and benefits in allo-HCT and irEC; our clinical development plans for SER-155; the timing and results of clinical studies and data readouts; current or future product candidates and their potential impacts and outcomes; our ability to obtain funding or enter into partnerships; the anticipated timing of any of the foregoing; and other statements that are not historical fact.

These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: (1) our need for additional funding; (2) our ability to continue as a going concern; (3) we have incurred significant losses, are not currently profitable and may never become profitable; (4) our cost reduction actions may not achieve their intended benefits, including an extended cash runway; (5) our limited operating history; (6) we may not be able to realize the anticipated benefits of the VOWST sale, and may face new challenges as a smaller, less diversified company; (7) we have in the past and may in the future receive notice of the failure to satisfy a continued listing rule from The Nasdaq Stock Market LLC; (8) our novel approach to therapeutic intervention; (9) our reliance on third parties to conduct our clinical trials and manufacture our product candidates; (10) our ability to achieve market acceptance necessary for commercial success; (11) the competition we will face; (12) our ability to protect our intellectual property; (13) impact of our recent management transitions and appointments and our ability to retain key personnel; and (14) disruptions at the FDA or other government agencies. These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the Securities and Exchange Commission (SEC), as well as our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Investor and Media Contact:
IR@serestherapeutics.com

Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com

TORONTO, Nov. 03, 2026 (GLOBE NEWSWIRE) — Fury Gold Mines Limited (TSX and NYSE American: FURY) (“Fury” or the “Company”) is pleased to announce first assay results from its 2026 diamond drill program at the Committee Bay gold project (“Committee Bay” or the “Project”), located in the eastern Kitikmeot region of Nunavut.

The 2026 drill program comprised 11 diamond drill holes totalling 4,219 metres (m), including five infill holes at the Three Bluffs deposit (Figure 1). The reported results come from infill drilling designed to increase drill density within the main portion of the existing Three Bluffs mineral resource and support improved confidence in geological and grade continuity.

Significant drill highlights, shown in true widths, include:

  • Hole 26TB158 intersected 3.88 grams per tonne (“g/t”) gold (“Au”) over 17.82 m, including 18.78 g/t Au over 3.30 m
  • Hole 26TB161 intersected 0.77 g/t Au over 98.60 m, including 65.60 g/t Au over 0.56 m, the widest mineralized interval drilled to date
  • Hole 26TB160 intersected 0.92 g/t Au over 31.45 m, including 12.35 g/t Au over 1.18 m, and 0.99 g/t Au over 28.83 m
  • Hole 26TB163 intersected 0.72 g/t Au over 36.58 m, including 2.65 g/t Au over 3.31 m
  • All five holes intersected the Three Bluffs shear zone, with widths ranging from 17 m to 99 m
  • 4,219 m (or 11 drill holes), including one abandoned hole, for the 2026 Committee Bay program has been completed. Assay results are pending for five of these holes, two of which are extension holes.

Results are highlighted by drill hole 26TB158, which intersected 3.88 g/t gold over 17.82 m, including a high-grade core of 18.78 g/t gold over 3.30 m, at a relatively shallow depth of 190 m. The hole was drilled within a broadly spaced area measuring 120 m by 220 m, demonstrating the continuity of mineralization across a large volume. The hole also returned a broad zone of lower-grade mineralization grading 0.39 g/t gold over 38.97 m immediately down-hole within the principal intercept (Figure 3). This intercept further demonstrates the scale and continuity of mineralization within the deposit and supports confidence in the Company’s geological model. The results are expected to be incorporated into the upcoming mineral resource update, contributing to increased resource confidence and supporting ongoing advancement of the project.

Drilling also returned broad zones of gold mineralization across the deposit, highlighted by hole 26TB161, which intersected 0.77 g/t gold over 98.60 m, including 65.60 g/t gold over 0.56 m, representing the widest mineralized interval drilled to date at Three Bluffs. Additional results include hole 26TB160, which intersected two mineralized zones grading 0.92 g/t gold over 31.45 m, including 12.35 g/t gold over 1.18 m, and 0.99 g/t gold over 28.83 m, including 3.50 g/t gold over 1.85 m (Figure 4). While hole 26TB163 returned 0.72 g/t gold over 36.58 m, including 2.65 g/t gold over 3.31 m, and hole 26TB162 returned 0.67 g/t gold over 17.36 m and 0.45 g/t gold over 20.98 m (Figure 4).

All holes disclosed in this news release, as well as the pending holes from the 2026 Committee Bay program, will be incorporated into the upcoming mineral resource estimate update for the Project. To date, 11 drill holes totalling approximately 4,219 metres have been completed, of which one hole was abandoned, and five holes are pending assay results. While the five holes reported in this release are infill holes, two of the five pending holes were designed as extension holes to define the extent of mineralization. The infill results give the Company confidence in the deposit as it continues exploring at depth and testing the full limits of the Three Bluffs resource.

“All five of our holes hit the Three Bluffs shear zone, which is exactly what this drill program was designed to confirm,” commented Tim Clark, CEO of Fury. “Hole 26TB158 stands out, returning 3.88 g/t gold over nearly 18 metres with a high-grade core of 18.78 g/t over 3.3 metres, and is a good example of the broad, continuous mineralization that has become a key differentiator of the Committee Bay project. The results strengthen our confidence in the scale of the Project as we continue to grow ounces ahead of the upcoming mineral resource update. With extension results pending, we look forward to further defining the size and potential of the Three Bluffs deposit.”

Table 1: Recent Drill Highlights

Hole ID   From (m) To (m) Core Length (m) True Width (m) Au (g/t)
26TB158   214.00 215.00 1.00 0.82 0.65
  220.00 241.60 21.60 17.82 3.88
Incl. 233.00 237.00 4.00 3.30 18.78
  256.00 257.00 1.00 0.83 0.41
  265.00 311.00 46.00 38.97 0.39
26TB160   225.00 231.00 6.00 3.35 1.13
  248.00 303.00 55.00 31.45 0.92
Incl. 301.00 303.00 2.00 1.18 12.35
  333.00 380.00 47.00 28.83 0.99
Incl. 341.00 347.00 6.00 3.65 2.17
and incl. 354.00 357.00 3.00 1.85 3.50
26TB161   230.00 408.00 178.00 98.60 0.77
Incl. 401.00 402.00 1.00 0.56 65.60
26TB162   226.00 258.00 32.00 17.36 0.67
  272.00 310.00 38.00 20.98 0.45
26TB163   309.00 385.00 76.00 36.58 0.72
Incl. 313.00 320.00 7.00 3.31 2.65

True widths are calculated using an interpreted mineralized domain of dip 80–89° as indicated for each hole. Reported intervals are length-weighted average gold grades. Composites require a minimum grade×thickness of 0.25 g/t·m, a minimum grade of 0.25 g/t gold and a maximum of 6 m of consecutive internal dilution; sub-intervals require a minimum grade×thickness of 5 g/t·m, a minimum grade of 2.00 g/t gold and a maximum of 2.5 m of consecutive internal dilution.

Figure1

Figure 1: Committee Bay, 2026 Exploration Program Location

Figure2

Figure 2: Three Bluffs – Longitudinal Section

Figure3

Figure 3: Three Bluffs – Drill Hole 26TB158 Cross Section

Figure4

Figure 4: Three Bluffs – Drill Hole 26TB160 Cross Section

Three Bluffs Deposit

The high-grade Three Bluffs Gold deposit is located centrally within the Committee Bay project and is estimated to contain 524,000 oz of gold in 2.1 million tonnes (Mt) at 7.85 g/t gold in the indicated mineral resource category and 720,000 oz in 2.9 Mt of gold at 7.64 g/t gold in the inferred mineral resource category (see Committee Bay NI 43-101 report “Technical Report on the Committee Bay Project, Nunavut Territory, Canada” dated September 11, 2023).

Valérie Doyon, P.Geo, VP of Geology at Fury, is a “qualified person” within the meaning of Canadian mineral projects disclosure standards instrument 43-101 and has reviewed and approved the technical disclosures in this press release.

Committee Bay Drilling QA/QC Disclosure

Intercepts at Three Bluffs were calculated using a minimum of a 2.0 g/t gold cut off at the beginning and end of the intercept and allowing for no more than 2.5 consecutive metres of less than 2.0 g/t gold. Minimum length of the composite allowed was one metre.

2026 Core (Diamond) Drilling

Analytical samples were taken by sawing NQ diameter core into equal halves on site and sent one of the halves to ALS Lab in Yellowknife, NWT for preparation and then to ALS Lab in Vancouver, BC for analysis. All samples are assayed using 50g nominal weight fire assay with atomic absorption finish (Au-AA26) and multi-element four acid digest ICP-AES/ICP-MS method (ME-MS61). QA/QC programs using internal standard samples, field and lab duplicates and blanks indicate good accuracy and precision in a large majority of standards assayed.

About Fury Gold Mines Limited

Fury Gold Mines Limited is a well-financed Canadian-focused exploration company advancing the Eau Claire gold project towards development, which holds a 5.8% equity position in Contango Silver and Gold Inc. Led by a management team and board of directors with proven success in financing and advancing exploration assets, Fury intends to grow its gold portfolio through rigorous project evaluation and exploration excellence. Fury is committed to upholding the highest industry standards for corporate governance, environmental stewardship, community engagement and sustainable mining. For more information on Fury Gold Mines, visit www.furygoldmines.com.

For further information on Fury Gold Mines Limited, please contact:

Margaux Villalpando, Investor Relations
Tel: (844) 601-0841
Email: info@furygoldmines.com
Website: www.furygoldmines.com

Forward-Looking Statements and Additional Cautionary Language

This news release includes certain statements that may be deemed to be “forward-looking statements” within the meaning of applicable securities laws, which statements relate to the future exploration operations of the Company and may include other statements that are not historical facts. Specific forward-looking statements contained in this news release include information relating to the Company’s ongoing 2026 exploration program at the Committee Bay project and to the preparation, timing and anticipated content of an updated mineral resource estimate for the Three Bluffs deposit.

Although the Company believes that the assumptions and expectations reflected in those forward-looking statements were reasonable at the time such statements were made, there can be no certainty that such assumptions and expectations will prove to be materially correct. Mineral exploration is a high-risk enterprise.

Readers should refer to the risks discussed in the Company’s Annual Information Form and MD&A for the year ended December 31, 2025 and subsequent continuous disclosure filings with the Canadian Securities Administrators available at www.sedarplus.ca and the Company’s Annual Report available at www.sec.gov. Readers should not place heavy reliance on forward-looking information, which is inherently uncertain.

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/d0d10019-34cb-47bc-b5bd-961add2a7ec6

https://www.globenewswire.com/NewsRoom/AttachmentNg/5a55b537-0775-43cf-9d54-43b3603f2fc3

https://www.globenewswire.com/NewsRoom/AttachmentNg/d9c151a6-beb5-4a51-95ce-1542d5470509

https://www.globenewswire.com/NewsRoom/AttachmentNg/f9ada21c-803a-48c4-ac81-6cc201963398 

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced it will report its third quarter 2026 financial results after market close on Tuesday, November 10, 2026.

Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and provide a corporate update.

The live webcast and archived replay of the event will be available in the Events and Presentations section of the Investors tab on the Company’s website at www.kuraoncology.com.

About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us X and LinkedIn.

Kura Contact

Investors and Media:
Greg Mann
gmann@kuraoncology.com

PRINCETON, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) — ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company’s executive leadership team, will participate in presentations and fireside chats at the following upcoming investor conferences:

Event Guggenheim 3rd Annual Healthcare Innovation Conference
Date Tuesday, November 10, 2026
Time 1:30 p.m. ET
Webcast Click here
   
Event 2026 Jefferies Global Healthcare Conference in London
Date Tuesday, November 17, 2026
Time 9:30 a.m. GMT
Webcast Click here
   

The live and archived webcasts will also be accessible from the Company’s website at www.anipharmaceuticals.com, in the Investors section under Events and Presentations.

About ANI

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives” by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit https://www.anipharmaceuticals.com.

Investor Relations:
Irina Koffler, Vice President, Investor Relations
T: 917-734-7387
E: Irina.koffler@anipharmaceuticals.com

Media Relations:
Argot Partners
T: 212-600-1494
E: ani@argotpartners.com

SOURCE: ANI Pharmaceuticals, Inc.

Strong financial results and cash generation

Revenue up 4%; GAAP EPS up 18% and Adjusted EPS up 4%

Year-to-date GAAP Operating Cash Flows up 16%, Adjusted Free Cash Flow (including swaps) up 46%

Returned $748 million to shareholders year-to-date through share repurchases and dividends

BOCA RATON, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) — ADT Inc. (NYSE: ADT), a leading provider of security, interactive, and smart home solutions serving residential and small business customers in the U.S., today reported results for the third quarter of 2026. Financial highlights for the third quarter are set forth below with variances on a year-over-year basis unless otherwise noted.

  • Total revenue increased 4% to $1.3 billion
  • Solid core operating metrics with end-of-period recurring monthly revenue (RMR) of $360 million, gross revenue attrition of 13.1%, and revenue payback at 2.3 years
  • GAAP income from continuing operations of $153 million, or $0.20 per diluted share, up $9 million
  • Adjusted income from continuing operations of $176 million, or $0.24 per diluted share, down $11 million
  • Net cash provided by operating activities of $440 million, down $40 million; Adjusted Free Cash Flow (including interest rate swaps) of $217 million, up $8 million

“ADT delivered solid third quarter results, with revenue growth, strong year-to-date cash generation and stable core operating metrics, reflecting the durability of our business and the dedication of our more than 12,000 employees,” said ADT Chairman, President and CEO, Jim DeVries. “We are making meaningful progress in transforming ADT into a more intelligent and connected platform through investments in AI, next-generation sensing technologies, and expanded digital and retail distribution. As we look ahead to our next chapter, our focus remains on serving our customers and providing peace of mind.”

Pending Acquisition by Thrive Holdings

On October 29, 2026, the Company announced that it has entered into a definitive agreement to be acquired by Thrive Holdings in an all-cash transaction. Under the terms of the agreement, which ADT’s Board of Directors unanimously approved, stockholders will receive $10.00 per share in cash upon completion. The transaction is expected to close in the first quarter of 2027, subject to customary closing conditions, including approval by stockholders and receipt of U.S. antitrust approval. Until the transaction closes, ADT will continue to operate independently as a public company. Following completion, ADT will become privately held, and its common stock will cease trading on the New York Stock Exchange. In consideration of the pending transaction, the Company is not providing financial guidance and is withdrawing previously issued guidance.

Business Highlights

Innovative Offerings, Unrivaled Safety and Premium Experience: The Company is undertaking focused initiatives to drive growth, strengthen brand loyalty, and improve customer acquisition efficiency while advancing its core mission of providing peace of mind. Recent progress on these initiatives is described below.

  • Expanding intelligent home innovation – Introduced Unusual Activity Alerts in ADT+, leveraging connected device and sensor data to identify meaningful changes in household activity and provide proactive customer notifications.
     
  • Progressing next-generation presence sensing – Advanced Origin AI-powered presence sensing capabilities, including ADT+ integration, development of future security and aging in place use cases, and commercialization planning for 2027 launch.
     
  • Scaling AI across customer experience – Continued expanding AI-enabled sales and service capabilities including intelligent call routing, AI-driven inbound and outbound sales and service pilots, and more advanced transcription and agent assist capabilities to handle increasingly complex customer interactions.
     
  • Broadening customer choice and market reach – Expanded ADT Blu to Walmart.com, increasing nationwide consumer access to ADT’s DIY security offering and broadening offerings across more customer segments and distribution channels.
     
  • Advancing ADT+ platform across channels – Continued the phased rollout of ADT+ for dealer-generated new customer additions, extending the Company’s technology platform and supporting a more consistent customer experience across channels.
     
  • Extending professional installation reach – Launched ADT Partner Services, a new offering that brings ADT’s trusted brand, field expertise and national reach to more companies and customers. Through this offering, the Company will install and service select products for Apple Retail and its customers in the U.S. beginning this fall.
     
  • Strengthening community engagement impact and first responder partnerships – Expanded ADT’s signature Life Saver program with a community event in Houston and continued to support National Night Out celebrations across the country, reinforcing ADT’s commitment to safer communities.

Unlocking Shareholder Value: The Company remained focused on continuing to generate significant cash flow, enabling direct capital returns to shareholders while maintaining a healthy balance sheet.

  • Share repurchases – During the third quarter, the Company repurchased and retired 3 million shares of its common stock for an aggregate price of $23 million. Year to date, the Company has repurchased and retired 89 million shares of its common stock for an aggregate price of $617 million.
     
  • Enhancing financial flexibility – In August, the Company secured $100 million of incremental borrowings under the First Lien Term Loan A due 2030, further strengthening the Company’s financial flexibility.
     
  • Strategic bulk account purchase – The Company completed a bulk purchase of approximately 8,000 customer accounts for $9 million cash.

Results of Operations (1)(2)

(in millions, except revenue payback, attrition, and per share data)   Three Months Ended September 30,
    2026       2025     Change   % Change
  GAAP
Monitoring and related services   $ 1,084     $ 1,098     $ (14 )   (1 )%
Security installation, product, and other     265       200       65     32 %
Total revenue   $ 1,349     $ 1,298     $ 51     4 %
                 
Income (loss) from continuing operations   $ 153     $ 144     $ 9     7 %
Income (loss) from continuing operations per share – diluted   $ 0.20     $ 0.17     $ 0.03     18 %
                 
Net cash provided by (used in):                
Operating activities   $ 440     $ 480     $ (40 )   (8 )%
Investing activities   $ (233 )   $ (298 )   $ 65     22 %
Financing activities   $ 19     $ (163 )   $ 183     112 %
                 
    Non-GAAP Measures
Adjusted EBITDA from continuing operations   $ 665     $ 676     $ (11 )   (2 )%
Adjusted income (loss) from continuing operations   $ 176     $ 187     $ (11 )   (6 )%
Adjusted EPS   $ 0.24     $ 0.23     $ 0.01     4 %
Adjusted Free Cash Flow (including interest rate swaps)   $ 217     $ 208     $ 8     4 %
                 
    Other Measures
Trailing twelve-month revenue payback   2.3 years   2.3 years   — years   — %
Trailing twelve-month gross customer revenue attrition     13.1 %     13.0 %   10 bps   N/A  
RMR   $ 360     $ 362     $ (3 )   (1 )%
                               

Total revenue was $1,349 million for the third quarter, up 4%. The increase was primarily driven by higher security installation, product, and other revenue due to an increase in the mix of professionally installed systems under the outright sales model. The decrease in Monitoring and related services (M&S) revenue reflects lower sales volume including the revenue loss from the October 2025 divestiture of the multifamily business, partially offset by higher average prices.

Income from continuing operations was $153 million, or $0.20 per diluted share, for the third quarter, up $9 million. This was driven by higher revenue, net of related costs, partially offset by higher selling, general, and administrative expenses, including the impact of the prior year goodwill impairment related to the divestiture of the multifamily business. Income from continuing operations also benefited from lower interest, including the impact of interest rate swaps.

Adjusted income from continuing operations was $176 million, or $0.24 per diluted share, for the third quarter, down $11 million, driven primarily by the same factors noted above excluding the prior year goodwill impairment and impact of interest rate swaps.

In addition to the factors above, earnings per share metrics benefited from a lower weighted-average diluted share count as a result of share repurchases.

Balance Sheet and Cash Flow

For the third quarter, net cash provided by operating activities was $440 million, down $40 million, primarily reflecting higher net subscriber acquisition spend related to outright sales transactions, higher general and administrative expenses, and lower M&S margins, partially offset by lower cash taxes and favorable working capital timing. Adjusted Free Cash Flow (including interest rate swaps) was $217 million, up $8 million. This measure includes the same factors above excluding the subscriber acquisition impact from the transition to an outright sales model.

In August, the Company secured $100 million of incremental borrowings under its First Lien Term Loan A due 2030, further enhancing financial flexibility and supporting general corporate purposes, which may include the repayment of a portion of the Company’s 2027 notes.

Total cash and cash equivalents as of September 30, 2026 were $228 million and no amounts were outstanding under the Company’s First Lien Revolving Credit Facility.

The Company returned $64 million of capital to shareholders during the quarter, including $23 million of share repurchases and $41 million of dividend payments. Through the end of the third quarter, the Company has repurchased 89 million shares returning $748 million to shareholders through share repurchases and dividends.

_____________________
(1)   All variances are year-over-year unless otherwise noted. The Company may sometimes present various non-GAAP and other operating measures. Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Free Cash Flow, Adjusted Free Cash Flow (including interest rate swaps), Adjusted Income (Loss), Adjusted Diluted Income (Loss) per share (or, Adjusted EPS), Net Debt, and Net Leverage Ratio are non-GAAP measures. Refer to the “Non-GAAP Measures” section for the definitions of the terms and reconciliations to the most comparable GAAP measures for those measures included herein. Operating metrics such as Gross Customer Revenue Attrition, Unit Count, RMR, Gross RMR Additions, and Revenue Payback are approximated as there may be variations to reported results in each period due to certain adjustments the Company might make in connection with the integration over several periods of acquired companies that calculated these metrics differently, or otherwise, including periodic reassessments and refinements in the ordinary course of business. These refinements, for example, may include changes due to systems conversion or historical methodology differences in legacy systems. Results of the former commercial and solar businesses are presented as discontinued operations. Except for cash flow measures, and unless otherwise noted, amounts herein reflect the results of the Company’s continuing operations only.
(2)   Amounts may not sum due to rounding.


Conference Call

As previously announced, management will host a conference call at 10 a.m. ET today to discuss the Company’s third quarter 2026 results. In consideration of the proposed acquisition of ADT by Thrive Holdings announced on October 29, 2026, the Company will not be taking questions on the call.  Participants may listen to a live webcast through the investor relations website at investor.adt.com. Alternatively, participants may listen to the live call by dialing 1-833-461-5787 (toll-free) or 1-585-542-9983 and providing the access code 472959920. A replay of the webcast will be available on the website within 24 hours after the event.

A slide presentation highlighting the Company’s results will also be available on the Investor Relations section of the Company’s website. From time to time, the Company may use its website as a channel of distribution of material Company information. Financial and other material information regarding the Company is routinely posted on and accessible at investor.adt.com.

About ADT Inc.

ADT is a leading provider of security, interactive, and smart home solutions serving residential and small business customers in the U.S. Through innovative offerings, unrivaled safety, and a premium customer experience delivered by the largest network of smart home security professionals in the U.S., ADT empowers people to protect and connect to what matters most, every second, every day. For more information, visit www.adt.com.

Forward-Looking Statements

ADT has made statements in this press release that are forward-looking and therefore subject to risks and uncertainties, including those described below. All statements, other than statements of historical fact, included in this document are, or could be, “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) and are made in reliance on the safe harbor protections provided thereunder. These forward-looking statements relate to, among other things, the Company’s capital allocation priorities and commitments; the Company’s partnership programs and the bulk purchase of customer accounts; initiatives with respect to the Company’s products and services, including ADT+, ADT Blu, Origin AI’s presence sensing technology, and the expected benefits and capabilities of such products and services; the Company’s ability to successfully execute and scale its DIY offerings, including through the expansion of its retail and e-commerce distribution channels; the Company’s development, deployment, and integration of AI in its products, services, and operations, including AI-driven customer interactions, virtual agents, operational efficiencies, and home intelligence capabilities; and the expectations, plans and objectives of management; any stated or implied outcomes with regard to the foregoing; and other matters. Without limiting the generality of the preceding sentences, any time we use the words “ongoing,” “expects,” “intends,” “will,” “anticipates,” “believes,” “confident,” “possible,” “continue,” “propose,” “seeks,” “could,” “may,” “should,” “estimates,” “forecasts,” “might,” “potential,” “outlook,” “goals,” “objectives,” “targets,” “planned,” “projects,” and, in each case, their negative or other various or comparable terminology, and similar expressions, we intend to clearly express that the information deals with possible future events and is forward-looking in nature. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. These forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. We caution that these statements are subject to risks and uncertainties, many of which are outside of the Company’s control and could cause future events or results to be materially different from those stated or implied in this press release, including, among others, the risk that the proposed transaction with Thrive Holdings announced on October 29, 2026 (the “Proposed Merger”) may not be completed in a timely manner or at all; the failure to receive, on a timely basis or otherwise, the required approvals of the Proposed Merger by the Company’s stockholders; the possibility that any or all of the various conditions to the consummation of the Proposed Merger may not be satisfied or waived, including the failure to receive any required regulatory approvals from any applicable governmental entities (or any conditions, limitations or restrictions placed on such approvals); the possibility that competing offers or acquisition proposals for the Company will be made; the occurrence of any event, change or other circumstance that could give rise to the termination of the definitive transaction agreement relating to the Proposed Merger, including in circumstances which would require the Company to pay a termination fee; the effect of the announcement or pendency of the Proposed Merger on the Company’s ability to attract, motivate or retain key executives and employees, its ability to maintain relationships with its customers, suppliers and other business counterparties, or its operating results and business generally; risks related to the Proposed Merger diverting management’s attention from the Company’s ongoing business operations; the risk of stockholder litigation in connection with the Proposed Merger, including resulting expense or delay; risks and uncertainties related to the Company’s divestiture of its commercial business (the “Commercial Divestiture”) and the Company’s exit from its residential solar business (the “ADT Solar Exit”); the Company’s ability to successfully integrate the acquisition of Origin AI and realize expected benefits of the acquisition; the Company’s ability to execute on transformation initiatives, including technology initiatives related to artificial intelligence and whole-home intelligence; the Company’s ability to maintain and grow the Company’s existing customer base, including the conversion of customers who continue to utilize outdated technology, and to integrate strategic bulk purchases of customer accounts; the impact of cyber attacks or related breaches with respect to information technology systems, cybersecurity, or data security involving the Company, our business partners, or other third parties whose systems are interconnected with ours, and any future or still undetected attacks or incidents; any material changes to the valuation allowances the Company takes with respect to its deferred tax assets; any changes in regulations or laws, global, economic, sovereign, political, or financial conditions, including labor and tax law changes or any impacts on the global economy or consumer discretionary spending due to tariffs or otherwise, changes to privacy requirements, changes to telemarketing, email marketing and similar consumer protection laws, interest rate volatility, and trade tariffs and restrictions applicable to the products we sell; the Company’s dependence on third-party providers, suppliers, dealers, and retail partners to enable it to produce and distribute its products and services in a cost-effective manner that protects the Company’s brand; the Company’s ability to effectively implement its strategic partnership with, and utilize any of the amounts invested by, Google; the Company’s ability to expand ADT+ and achieve expected adoption and customer engagement; risks related to the Company’s use of AI in its products, services, and operations, including evolving legal and regulatory requirements, technological limitations, potential liability, and reputational concerns; the expected shift in the Company’s transaction mix (including increased outright equipment sales) and the related effects on the timing and mix of revenue and costs; and risks that are described in the Company’s most recently filed Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, including the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained in those reports, and in the Company’s other filings with the SEC. Any forward-looking statement made in this press release speaks only as of the date on which it is made. ADT undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise, unless required by law.

 
ADT INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in millions, except per share data) (Unaudited)
 
    Three Months Ended September 30,   Nine Months Ended September 30,
      2026       2025     $
Change
  %
Change
    2026       2025     $
Change
  %
Change
Revenue:                                
Monitoring and related services   $ 1,084     $ 1,098     $ (14 )   (1)%   $ 3,246     $ 3,271     $ (25 )   (1)%
Security installation, product, and other     265       200       65     32%     693       582       112     19%
Total revenue     1,349       1,298       51     4%     3,940       3,852       87     2%
Cost of revenue (exclusive of depreciation and amortization shown separately below):                                
Monitoring and related services     160       162       (2 )   (1)%     472       482       (10 )   (2)%
Security installation, product, and other     133       89       44     50%     327       259       68     26%
Total cost of revenue     293       251       42     17%     799       741       58     8%
Selling, general, and administrative expenses     400       384       16     4%     1,151       1,109       42     4%
Depreciation and intangible asset amortization     345       348       (3 )   (1)%     1,038       1,026       12     1%
Operating income (loss)     311       315       (5 )   (1)%     952       976       (24 )   (3)%
Interest expense, net     (102 )     (113 )     11     (10)%     (302 )     (349 )     47     (13)%
Other income (expense)     —       (4 )     4     N/M     3       (8 )     11     N/M
Income (loss) from continuing operations before income taxes     209       199       11     5%     653       619       34     5%
Income tax benefit (expense)     (57 )     (55 )     (1 )   3%     (175 )     (165 )     (11 )   6%
Income (loss) from continuing operations     153       144       9     7%     477       454       23     5%
Income (loss) from discontinued operations, net of tax     (2 )     2       (4 )   N/M     (4 )     (4 )     (1 )   22%
Net income (loss)   $ 151     $ 145     $ 5     4%   $ 473     $ 451     $ 22     5%
                                 
Common Stock:                                
Income (loss) from continuing operations per share – basic   $ 0.21     $ 0.18             $ 0.62     $ 0.54          
Income (loss) from continuing operations per share – diluted   $ 0.20     $ 0.17             $ 0.59     $ 0.51          
                                 
Net income (loss) per share – basic   $ 0.21     $ 0.18             $ 0.62     $ 0.54          
Net income (loss) per share – diluted   $ 0.19     $ 0.16             $ 0.57     $ 0.50          
                                 
Weighted-average shares outstanding – basic     676       765               714       783          
Weighted-average shares outstanding – diluted     737       828               774       846          
                                 
Class B Common Stock:                                
Income (loss) from continuing operations per share – basic   $ 0.21     $ 0.18             $ 0.62     $ 0.54          
Income (loss) from continuing operations per share – diluted   $ 0.20     $ 0.17             $ 0.59     $ 0.51          
                                 
Net income (loss) per share – basic   $ 0.21     $ 0.18             $ 0.62     $ 0.54          
Net income (loss) per share – diluted   $ 0.19     $ 0.16             $ 0.57     $ 0.50          
                                 
Weighted-average shares outstanding – basic     55       55               55       55          
Weighted-average shares outstanding – diluted     55       55               55       55          

Note: amounts may not sum due to rounding

ADT INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in millions) (Unaudited)
 
  September 30, 2026   December 31, 2025
Assets      
Current assets:      
Cash and cash equivalents $ 228   $ 81
Restricted cash and restricted cash equivalents   26     28
Accounts receivable, net   373     385
Inventories, net   177     202
Prepaid expenses and other current assets   163     250
Total current assets   967     946
Property and equipment, net   288     243
Subscriber system assets, net   2,630     2,791
Intangible assets, net   4,769     4,818
Goodwill   4,992     4,886
Deferred subscriber acquisition costs, net   1,553     1,452
Other assets   753     683
Total assets $ 15,953   $ 15,819
       
Liabilities and stockholders’ equity      
Current liabilities:      
Current maturities of long-term debt $ 1,242   $ 310
Accounts payable   163     107
Deferred revenue   245     244
Accrued expenses and other current liabilities   423     352
Total current liabilities   2,073     1,013
Long-term debt   6,539     7,379
Deferred subscriber acquisition revenue   2,028     2,084
Deferred tax liabilities   1,316     1,267
Other liabilities   358     297
Total liabilities   12,312     12,040
       
Total stockholders’ equity   3,640     3,779
Total liabilities and stockholders’ equity $ 15,953   $ 15,819

Note: amounts may not sum due to rounding

ADT INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in millions)  (Unaudited)
 
  Three Months Ended
September 30,
  Nine Months Ended
September 30,
    2026       2025       2026       2025  
Cash flows from operating activities:              
Net income (loss) $ 151     $ 145     $ 473     $ 451  
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:              
Depreciation and intangible asset amortization   345       348       1,038       1,026  
Amortization of deferred subscriber acquisition costs   71       64       207       187  
Amortization of deferred subscriber acquisition revenue   (88 )     (90 )     (267 )     (268 )
Share-based compensation expense   19       11       51       43  
Deferred income taxes   7       44       24       46  
Provision for losses on receivables and inventory   52       55       170       156  
Loss on extinguishment of debt   —       5       —       11  
Goodwill, intangible, and other asset impairments   —       14       —       15  
Unrealized (gain) loss on interest rate swap contracts   9       15       26       57  
Other non-cash items, net   22       14       55       53  
Changes in operating assets and liabilities, net of effects of acquisitions and dispositions:              
Deferred subscriber acquisition costs   (115 )     (99 )     (309 )     (288 )
Deferred subscriber acquisition revenue   41       58       139       173  
Other, net   (72 )     (103 )     137       (151 )
Net cash provided by (used in) operating activities   440       480       1,745       1,511  
               
Cash flows from investing activities:              
Dealer generated customer accounts and bulk account purchases   (124 )     (157 )     (363 )     (488 )
Subscriber system asset expenditures   (65 )     (98 )     (234 )     (307 )
Purchases of property and equipment   (46 )     (43 )     (141 )     (126 )
Acquisition of businesses, net of cash acquired   —       —       (164 )     —  
Proceeds (payments) from interest rate swaps   1       (1 )     2       (2 )
Other investing, net   —       —       —       2  
Net cash provided by (used in) investing activities   (233 )     (298 )     (900 )     (921 )
               
Cash flows from financing activities:              
Proceeds from long-term borrowings   115       610       364       1,340  
Repayment of long-term borrowings, including call premiums   (27 )     (627 )     (274 )     (1,278 )
Proceeds from receivables facility   51       60       155       207  
Repayment of receivables facility   (63 )     (59 )     (193 )     (174 )
Proceeds (payments) from interest rate swaps   15       17       39       51  
Repurchases of common stock, including excise tax   (23 )     (112 )     (623 )     (607 )
Dividends on common stock   (41 )     (46 )     (130 )     (142 )
Payments on finance leases   (8 )     (6 )     (23 )     (21 )
Other financing, net   —       —       (13 )     —  
Net cash provided by (used in) financing activities   19       (163 )     (699 )     (623 )
               
Cash and cash equivalents and restricted cash and restricted cash equivalents:              
Net increase (decrease)   227       19       146       (33 )
Beginning balance   28       152       109       204  
Ending balance $ 255     $ 171     $ 255     $ 171  

Note: amounts may not sum due to rounding

ADT INC. AND SUBSIDIARIES
NON-GAAP MEASURES

ADT sometimes uses information (“non-GAAP financial measures”) that is derived from the consolidated financial statements, but that is not presented in accordance with accounting principles generally accepted in the U.S. (“GAAP”). Under SEC rules, non-GAAP financial measures may be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for or superior to GAAP results.

The following information includes definitions of the Company’s non-GAAP financial measures used in this release, reasons management believes these measures are useful to investors regarding the Company’s financial condition and results of operations, additional purposes, if any, for which management uses the non-GAAP financial measures, and limitations to using these non-GAAP financial measures, as well as reconciliations of these non-GAAP financial measures to the most comparable GAAP measures. Each non-GAAP financial measure is presented following the corresponding GAAP measure so as not to imply that more emphasis should be placed on the non-GAAP measure. The limitations of non-GAAP financial measures are best addressed by considering these measures in conjunction with the appropriate GAAP measures. In addition, computations of these non-GAAP measures may not be comparable to other similarly titled measures reported by other companies.

Unless otherwise noted, non-GAAP measures herein reflect the results of the Company’s continuing operations.

Free Cash Flow, Adjusted Free Cash Flow, and Adjusted Free Cash Flow including interest rate swaps

The Company defines Free Cash Flow as cash flows from operating activities less cash outlays related to capital expenditures. The Company defines capital expenditures to include accounts purchased through the Company’s network of authorized dealers or third parties outside of the Company’s authorized dealer network, subscriber system asset expenditures, and purchases of property and equipment. These items are subtracted from cash flows from operating activities because they represent long-term investments that are required for normal business activities.

The Company defines Adjusted Free Cash Flow as Free Cash Flow adjusted for net cash flows related to (i) net proceeds or payments from the Company’s consumer receivables facility; (ii) restructuring and integration payments; (iii) integration-related capital expenditures; and (iv) transaction costs and other payments or receipts that may mask operating results or business trends. Adjusted Free Cash Flow including interest rate swaps reflects Adjusted Free Cash Flow plus net cash settlements on interest rate swaps presented outside of net cash provided by (used in) operating activities.

The Company believes the presentations of these non-GAAP measures are appropriate to provide investors with useful information about the Company’s ability to repay debt, pay dividends, repurchase shares, and make other investments. The Company believes the presentation of Adjusted Free Cash Flow is also a useful measure of the cash flow attributable to normal business activities, inclusive of the net cash flows associated with the acquisition of subscribers, as well as the Company’s ability to repay debt, pay dividends, repurchase shares, and make other investments. Further, Adjusted Free Cash Flow including interest rate swaps is a useful measure of Adjusted Free Cash Flow inclusive of all cash interest.

There are material limitations to using these non-GAAP measures. These non-GAAP measures adjust for cash items that are ultimately within management’s discretion to direct, and therefore, may imply that there is less or more cash available than the most comparable GAAP measure. These non-GAAP measures are not intended to represent residual cash flow for discretionary expenditures since debt repayment requirements and other non-discretionary expenditures are not deducted.

  Three Months Ended
September 30,
  Nine Months Ended
September 30,
(in millions)   2026       2025       2026       2025  
Net cash provided by (used in):              
Operating activities $ 440     $ 480     $ 1,745     $ 1,511  
Investing activities $ (233 )   $ (298 )   $ (900 )   $ (921 )
Financing activities $ 19     $ (163 )   $ (699 )   $ (623 )
               
Net cash provided by (used in) operating activities $ 440     $ 480     $ 1,745     $ 1,511  
Dealer generated customer accounts and bulk account purchases   (124 )     (157 )     (363 )     (488 )
Subscriber system asset expenditures   (65 )     (98 )     (234 )     (307 )
Purchases of property and equipment   (46 )     (43 )     (141 )     (126 )
Free Cash Flow   206       182       1,007       590  
Net proceeds (payments) from receivables facility   (11 )     1       (38 )     33  
Merger, restructuring and integration payments(1)   4       2       17       10  
Other, net(2)   3       6       10       26  
Adjusted Free Cash Flow $ 201     $ 192     $ 996     $ 659  
Interest rate swaps presented outside operating activities   15       16       41       49  
Adjusted Free Cash Flow (including interest rate swaps) $ 217     $ 208     $ 1,037     $ 709  

Note: amounts may not sum due to rounding
_______________________
(1)   During 2026, primarily includes payments related to the Origin AI Acquisition.
(2)   For 2025, primarily includes net outflows related to the former Solar Business and third-party costs associated with implementation of a new ERP system that the Company will not continue to incur once the ERP system is fully implemented.


Adjusted
EBITDA from Continuing Operations (“Adjusted EBITDA”) and Adjusted EBITDA Margin from Continuing Operations (“Adjusted EBITDA Margin”)

The Company defines Adjusted EBITDA as income (loss) from continuing operations adjusted for (i) interest; (ii) taxes; (iii) depreciation and amortization, including depreciation of subscriber system assets and other fixed assets and amortization of dealer and other intangible assets; (iv) amortization of deferred costs and deferred revenue associated with subscriber acquisitions; (v) share-based compensation expense; (vi) merger, restructuring, integration, and other items; (vii) impairment charges; and (viii) other non-cash or non-routine adjustments not necessary to operate our business.

The Company believes Adjusted EBITDA is useful to investors to measure the operational strength and performance of its business. The Company believes the presentation of Adjusted EBITDA is useful as it provides investors additional information about operating profitability adjusted for certain non-cash items, non-routine items the Company does not expect to continue at the same level in the future, as well as other items not core to its operations. Further, the Company believes Adjusted EBITDA provides a meaningful measure of operating profitability because the Company uses it for evaluating business performance, making budgeting decisions, and comparing company performance against other peer companies using similar measures.

There are material limitations to using Adjusted EBITDA as it does not include certain significant items which directly affect income (loss) from continuing operations (the most comparable GAAP measure).

The discussion above is also applicable to Adjusted EBITDA margin, which is calculated as Adjusted EBITDA as a percentage of total revenue.

  Three Months Ended
September 30,
(in millions)   2026       2025  
Income (loss) from continuing operations $ 153     $ 144  
Interest expense, net   102       113  
Income tax expense (benefit)   57       55  
Depreciation and intangible asset amortization   345       348  
Amortization of deferred subscriber acquisition costs   71       64  
Amortization of deferred subscriber acquisition revenue   (88 )     (90 )
Share-based compensation expense   19       11  
Merger, restructuring, integration and other(1)   2       6  
Goodwill impairment(2)   —       12  
Unrealized gain (loss) on interest rate swaps(3)   5       4  
Loss on extinguishment of debt   —       5  
Other, net(4)   1       5  
Adjusted EBITDA $ 665     $ 676  
       
Income (loss) from continuing operations to total revenue ratio   11 %     11 %
Adjusted EBITDA Margin (as percentage of Total Revenue)   49 %     52 %

Note: amounts may not sum due to rounding
_______________________
(1)   During 2026, primarily relates to the Origin AI Acquisition and restructuring expenses.
(2)   Represents a goodwill impairment charge associated with the Multifamily Divestiture.
(3)   Includes the unrealized gain or loss on interest rate swaps presented in other income (expense).
(4)   During 2025, primarily includes one-time costs associated with debt transactions.


Adjusted Income (Loss) from Continuing Operations (“Adjusted Income (Loss)”) and Adjusted Diluted Income (Loss) per Share from Continuing Operations (“Adjusted Diluted Income (Loss) per Share” or “Adjusted EPS”)

The Company defines Adjusted Income (Loss) as income (loss) from continuing operations adjusted for (i) share-based compensation expense; (ii) merger, restructuring, integration, and other items; (iii) impairment charges; (iv) unrealized (gains) or losses on interest rate swaps; (v) other non-cash or non-routine adjustments not necessary to operate our business; and (vi) the impact these items have on taxes.

The Company defines Adjusted EPS as diluted income (loss) from continuing operations per share adjusted for the per share amounts related to (i) share-based compensation expense; (ii) merger, restructuring, integration, and other items; (iii) impairment charges; (iv) unrealized (gains) or losses on interest rate swaps; (v) other non-cash or non-routine adjustments not necessary to operate our business; and (vi) the impact these items have on taxes.

Adjusted EPS equals Adjusted Income (Loss) divided by diluted weighted-average shares outstanding of common stock as calculated in accordance with GAAP. When the control number for the GAAP calculation is negative, diluted weighted-average shares outstanding of common stock does not include the assumed conversion of Class B common stock and other potential shares, such as share-based compensation awards, to shares of common stock.

The Company believes Adjusted Income (Loss) and Adjusted EPS are benchmarks used by analysts and investors who follow the industry for comparison of our performance with other companies in the industry, although these measures may not be directly comparable to similar measures reported by other companies. The Company believes the presentation of Adjusted EPS is useful to investors as it provides additional information about how our management evaluates the business. Management and the Board also use Adjusted EPS to evaluate the performance of employees (including members of management) and the Company as a whole, as well as to allocate resources.

There are material limitations to using these measures, as they do not reflect certain significant items which directly affect income (loss) from continuing operations and related per share amounts (the most comparable GAAP measures).

  Three Months Ended
September 30,
(in millions, except per share data)   2026       2025  
Income (loss) from continuing operations $ 153     $ 144  
Share-based compensation expense   19       11  
Merger, restructuring, integration, and other(1)   2       6  
Goodwill impairment(2)   —       12  
Interest rate swaps, net(3)   9       15  
Loss on extinguishment of debt   —       5  
Other, net   1       5  
Tax adjustments(4)   (7 )     (11 )
Adjusted Income (Loss) from continuing operations $ 176     $ 187  
       
Diluted weighted-average shares outstanding of Common Stock(5):   737       828  
       
Diluted income (loss) from continuing operations per share of Common Stock $ 0.20     $ 0.17  
Share-based compensation expense   0.03       0.01  
Merger, restructuring, integration, and other(1)   —       0.01  
Goodwill impairment(2)   —       0.01  
Interest rate swaps, net(3)   0.01       0.02  
Loss on extinguishment of debt   —       0.01  
Other, net(6)   0.01       0.01  
Tax adjustments(4)   (0.01 )     (0.01 )
Adjusted EPS $ 0.24     $ 0.23  

Note: amounts may not sum due to rounding.
_______________________

(1)   During 2026, primarily relates to the Origin AI Acquisition and restructuring expenses.
(2)   Represents a goodwill impairment charge associated with the Multifamily Divestiture.
(3)   Primarily includes unrealized (gains) or losses on interest rate swaps presented in interest expense, net and other income (expense).
(4)   Represents the tax impact on adjustments using the federal and state blended statutory rate.
(5)  Refer to the Company’s Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K for further discussion regarding the computation of diluted weighted-average shares outstanding of Common Stock.
(6)   Includes the impact related to the two-class method of EPS. Refer to the Company’s Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K.

CONTACT: Investor Relations:
investorrelations@adt.com
Tel: 888-238-8525

Media Relations:
media@adt.com

In its first run on a real quantum processor, Quantum X Labs’ Qatacomb scheme successfully recovered an encrypted image using a 156-qubit machine, while an adversary without the key gained no usable information in the demonstration, illustrating a privacy guarantee designed to hold regardless of an adversary’s computing power

TEL AVIV, Israel, Nov. 03, 2026 (GLOBE NEWSWIRE) — Gix Internet Ltd. (Nasdaq: GIXI; TASE: GIX) (“Gix” or the “Company”), a dual-listed technology company, today announced that Quantum X Labs Inc. (Nasdaq: QXL) (“Quantum X Labs” or “QXL”), in which Gix holds approximately 13% (2,818,585 shares), has reported the first demonstration of its Qatacomb quantum encryption scheme on commercial quantum hardware.

In a run on an IBM Quantum Heron r2 processor, programmed through IBM’s open-source Qiskit framework, the intended recipient reconstructed an encrypted image by reading through the machine’s own noise, while an adversary who did not hold the key gained no usable information about the message.

Quantum X Labs believes the significance lies in the kind of guarantee the scheme is designed to provide. Most encryption in use today rests on mathematical problems that are hard to solve with current computers, and a sufficiently capable quantum computer is widely expected to be able to break much of it. Qatacomb is instead designed so that its privacy follows from the structure of quantum states themselves: it is intended to be information-theoretic, meaning its security is not designed to depend on any assumption about how much computing power an adversary can bring to bear, now or in the future.

The demonstration moves Qatacomb from theory to testing on a real device. The intended recipient, holding the key, recovered the correct content for better than nine of every ten image elements and reconstructed the full image without error – despite the processor’s real noise. The adversary’s best possible measurement, evaluated exactly, returned no usable advantage.

About Gix Internet Ltd.

Gix Internet Ltd. is a technology company that is listed on the Nasdaq Capital Market under the symbol GIXI and on the Tel Aviv Stock Exchange under the symbol GIX. Its operating focus is deliverz.ai, a wholly-owned company that develops an AI-powered management and orchestration layer for robots, people and autonomous systems, commercially proven today in hospital logistics. The platform combines management software with autonomous mobile robots and human couriers to schedule and assign internal deliveries in real time – by location, priority and availability – from a central operations system. It is built for last-mile movement inside complex, high-traffic facilities such as hospitals, is in commercial use at Sheba Medical Center, and is being introduced to U.S. healthcare organizations. Gix’s broader strategy is to extend the same management architecture to additional autonomous systems and complex physical operating environments. Gix also holds a strategic minority stake in Quantum X Labs Inc., a separately listed company. For more information, visit https://www.gix-internet.com/.

About Quantum X Labs Inc.

Quantum X Labs Inc. and its subsidiaries are focused on quantum technology, digital advertising and computing and enterprise artificial intelligence (AI) solutions. Quantum X Labs Ltd. is focused on developing and promoting quantum algorithms for the transportation, drug discovery and security segments as well as developing quantum- based GPS replacement and quantum atom accuracy solutions. Gix Media develops a variety of technological software solutions, which perform automation, optimization and monetization of internet campaigns, for the purposes of acquiring and routing internet user traffic to its customers. Metagramm is a developer of grammatical error correction software and offers tools for writing and reviewing, grammar, spelling, punctuation and style features, as well as translation and multilingual dictionaries, using artificial intelligence and machine learning technology.

For more information about Quantum X Labs, visit https://quantumxlabs.xyz/

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Gix’s strategic and business plans, technology, relationships, objectives and expectations for its business, growth, the impact of trends on and interest in its business, intellectual property, products and its future results, operations and financial performance and condition and may be identified by the use of words such as “may,” “seek,” “will,” “consider,” “likely,” “assume,” “estimate,” “expect,” “anticipate,” “intend,” “believe,” “do not believe,” “aim,” “predict,” “plan,” “project,” “continue,” “potential,” “guidance,” “objective,” “outlook,” “trends,” “future,” “could,” “would,” “should,” “target,” “on track” or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. For example, the Company is using forward-looking statements when it discusses the intended security and privacy characteristics of Qatacomb, including its intended information-theoretic security and its design not to depend on assumptions regarding an adversary’s computing power; the potential significance, capabilities, benefits and applications of Qatacomb and QXL’s quantum encryption technologies; and QXL’s continued development, testing and commercialization of Qatacomb and its other quantum technologies. There can be no assurance that any benefit realized by QXL will result in any corresponding benefit to the Company or the value of its investment in QXL. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s registration statement on Form 20-F (File No. 001-43362), as amended, as filed with the SEC on June 18, 2026, and in subsequent filings with the SEC. For a description of risks affecting QXL, reference is made to QXL’s filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Gix is not responsible for the content of third-party websites. IBM, IBM Quantum and the names of IBM quantum processors are trademarks of International Business Machines Corporation; IBM is not affiliated with, and has not endorsed, Gix, QXL or the results described in this press release.

Investor Relations Contact:
Michal Efraty
Investor Relations
michal@efraty.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.